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ABSTRACT 
 
  Virus infection is sensed by the innate immune system through 
germline encoded pattern recognition receptors (PRRs). Toll-like receptors 
(TLRs), retinoic acid-inducible gene-I-like receptors (RLRs) and nucleotide-
binding oligomerization domain-like receptors (NLRs) serve as PRRs that 
recognize different viral components.  Microbial nucleic acids such as 
Ribonucleic acid (RNA) are important virus-derived pathogen-associated 
molecular patterns (PAMPs) to be recognized by PRRs. Virus recognition may 
occur at multiple stages of the viral life cycle. Replication intermediates such as 
single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) are detected 
by the RNA-sensing PRRs that initiate innate and adaptive immune responses. 
Triggering of the innate immune system is a critical event that can shape the 
adaptive immune response to virus infection. Better vaccination strategies that 
lead to improved T-cell and antibody responses are needed for protection against 
pathogens. We sought to delineate the RNA-sensing PRR pathways that are 
activated during infection with an RNA virus, the signaling mediators involved 
and the influence on subsequent virus-specific adaptive immune responses. 
 To analyze the role of RNA-sensing PRRs in T-cell immune responses in 
vitro, we performed direct co-stimulation experiments on CD4+ T-cells of high 
purity.  We utilized synthetic RNA-like immune response modifiers (IRMs) R-848 
(MyD88-dependent) and poly I:C (MyD88-independent)  as RNA PAMPs to 
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determine the direct effects of RNA-sensing PRR activation on CD4+ T-cells. 
RNA PAMPs can act directly on CD4+ T-cells and modulate their function and 
phenotype. Maximal direct co-stimulatory effects were observed in CD4+ T-cells 
cultured with poly I:C compared to R-848. The cytoplasmic dsRNA-dependent 
protein kinase R (PKR) was also involved in poly I:C-mediated signaling in CD4+ 
T-cells.  
We found differences in the RNA-sensing PRRs activated by R-848 
between mouse and human CD4+ T-cells. We observed minimal direct co-
stimulatory effects by R-848 in mouse CD4+ T-cells. In contrast, augmentation of 
Th1 responses by R-848 was observed in human CD4+ T-cells. TLR8 activation 
in human CD4+ T-cells may explain the observed differences. 
  We next explored the signaling pathways activated by RNA PAMPs in 
conventional dendritic cells (cDCs) and CD4+ T-cells that drive Th1 CD4 T-cell 
responses in isolated cDC/CD4 T-cell interactions. Allogeneic cDCs and CD4+ T-
cells of high purity were cultured together with R-848 and poly I:C in MHC 
congenic mixed leukocyte reactions (MLRs). R-848 and poly I:C stimulation of 
type I IFN production and signaling was essential but not sufficient for driving 
CD4+ Th1 responses. The early production of IL-1α and IL-1β was equally 
critical. 
To analyze the role of RNA-sensing PRRs in T-cell immune responses in 
vivo, we utilized a mouse model of heterosubtypic influenza A virus (IAV) 
infections. Using MyD88-/- , TLR7-/- and IL-1-deficient mice, we explored the role 
vi 
 
of MyD88-signaling in the generation of heterosubtypic memory CD4+ T-cell, 
CD8+ T-cell and antibody responses. We found that MyD88 signaling played an 
important role in anti-IAV spleen and lung CD4+ T-cell, spleen CD8+ T-cell and 
Th1 antibody immune responses. Anti-IAV lung heterosubtypic CD8+ T-cell 
responses were not dependent on MyD88 signaling.   
Our in vitro and in vivo results show the pivotal role of RNA-sensing PRR 
pathway activation in T-cell immune responses. Understanding the complexity of 
the PRR pathways involved during viral infections and defining the subsequent 
immune response would have important implications for the generation of more 
effective vaccine strategies. 
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CHAPTER I: 
INTRODUCTION 
 
 Over the past decade, there has been rapid advancement in our 
knowledge about the contributions of the innate immune system to the 
recognition of infection with RNA viruses. This initial host response is mediated 
by pattern recognition receptors (PRRs). These receptors are encoded by genes 
in the germline DNA and respond with the immediate activation of effectors. They 
do not require the gene rearrangements essential to recognition by the adaptive 
immune response (66). Sensing by PRRs of conserved molecular structures of 
pathogens, referred to as pathogen-associated molecular patterns (PAMPs), is 
the first crucial step in the development of virus-specific adaptive immune 
responses. To delineate the complexity of RNA-sensing PRR pathways that are 
activated during infection with an RNA virus, the signaling mediators involved 
and the subsequent adaptive immune responses is the focus of this dissertation. 
 
A. Pattern Recognition Receptors and Pathogen-Associated Molecular 
Patterns 
The recognition of evolutionarily conserved microbial structures, now 
known as PAMPs, was first proposed by Janeway in 1989 (64, 65). He proposed 
that the basis of pathogen non-self recognition lies in the ability of the host to 
recognize conserved microbial products or components that are unique to 
1
pathogens and are not produced by the host. This recognition, mediated by 
PRRs, allows for the innate immune system to discriminate between “infectious 
non-self” and “non-infectious self” (110). PRRs possess certain common 
characteristics: (i) PRRs recognize conserved molecular patterns that are 
essential to the virus or bacteria and are therefore difficult for the microbe to 
alter; (ii) PRRs are expressed constitutively in the host and detect the pathogen 
regardless of their life cycle; and (iii) PRRs are germline encoded, nonclonal and 
independent of immunologic memory (reviewed in (3)). Today, several 
structurally and functionally distinct classes of PRRs are known to recognize 
various PAMPs and induce various host defense pathways (reviewed in (83, 84)) 
(Table 1.1). The three major classes of PRRs are the Toll-like receptors (TLRs) 
that detect PAMPs either at the cell surface or in the lumen of intracellular 
vesicles; and the cytosolic PRRs retinoic acid-inducible gene-I (RIG-I)-like 
receptors (RLRs) and the nucleotide-binding oligomerization domain (NOD)-like 
receptors (NLRs) for the detection of intracellular PAMPs (82, 83, 113). 
 
i. Toll-like receptors (TLRs) 
TLRs are the most extensively studied class of PRRs. Discovered in the 
mid-1990’s to be structurally related to the Drosophila Toll (111, 135), TLRs are 
type I transmembrane proteins composed of three major domains – the 
ectodomain with leucine-rich repeats (LRRs) that mediate recognition of their 
respective PAMPs, the transmembrane domain and the intracellular domain that 
2
is homologous to the interleukin-1 receptor’s (IL-1R) Toll/IL-1 receptor homology 
(TIR) domain, which is required for downstream signal transduction (Figure 1.1) 
(reviewed in (82)). To date, there are more than 12 members of the mammalian 
TLR family. 10 TLRs have been identified to be functional in humans and 12 are 
functional in mice with TLR1-TLR9 being conserved in both species (82, 83). 
TLR10 in mice is non-functional due to a retrovirus insertion (45) while TLR11, 
TLR12 and TLR13 are believed to have been lost in the human genome (82).  
TLRs are largely divided into two sub-populations with regard to their 
cellular localization and respective PAMP ligands. One group is composed of 
TLR1, TLR2, TLR4, TLR5 and TLR6 that are localized on the cell surface and 
largely recognize microbial membrane components such as lipid, lipoproteins 
and proteins; the other group is composed of TLR3, TLR7, TLR8 and TLR9, 
which are expressed within intracellular vesicles and recognize microbial nucleic 
acids (Table  1.1) (reviewed in (84)). TLR4 is an exception. It is expressed on the 
cell surface, initially transmits signals for early phase activation and is then 
endocytosed and delivered to intracellular vesicles for the sequential induction of 
late-phase signaling pathways (8, 56, 72). TLR11, a relative of surface-
expressed TLR5, was recently shown to be also expressed in intracellular 
compartments (128) but is known to recognize the protozoan profilin-like protein 
(173). TLR13 is localized intracellularly; although the cognate PAMP is yet to be 
identified, it has been implicated to have a role in the recognition of vesicular 
stomatitis virus (146). 
3
Figure 1.1. Toll-like receptors.  The  mammalian homolog of the Drosophila Toll 
receptor. Toll-like receptors (TLRs) are type I transmembrane proteins with three major 
domains. The N-terminal pathogen-associated molecular pattern (PAMP)-binding 
ectodomain that contains multiple leucine-rich repeats (LRRs), the transmembrane 
domain and the intracellular domain of the interluekin-1 receptor (IL-1R) called Toll/IL-
1R homology (TIR) domain which mediates  signaling events upon receptor activation. 
LRRs 
TLR IL-1R 
Ig-like 
domain 
TIR 
domain 
transmembrane 
domain 
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Species PAMPs/Activators PRRs involved in recognition 
Bacteria, 
Mycobacteria 
LPS TLR4 
Lipoproteins, lipoteichoic acid, 
peptidoglycan, lipoarabinomannan 
TLR2/1, TLR2/6 
NOD1, NOD2, NALP3, NALP1 
flagellin TLR5 
IPAF, NAIP5 
DNA TLR9 
AIM2 
RNA TLR7 
NALP3 
Viruses DNA TLR9 
AIM2, DAI, IFI16, DDX41 
RNA TLR3, TLR7, TLR8 
RIG-I, MDA5, NALP3 
Structural protein TLR2, TLR4 
Fungus Zymosan, β-glucan TLR2, TLR6 
Dectin-1, NALP3 
Mannan TLR2, TLR4 
DNA TLR9 
RNA TLR7 
Parasites tGPI-mucin (Trypanosoma) TLR2 
Glycoinositolphospholipids 
(Trypanosoma) 
TLR4 
DNA TLR9 
Hemozoin (Plasmodium) TLR9 
Profilin-like molecule TLR11 
Table 1.1.  PRRs and PAMPs 
* Adapted from Kawaii and Akira, 2011  
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There are four known signaling adaptors in TLR signaling: MyD88, 
MyD88-adaptor-like (MAL, also known as TIRAP), TIR-domain containing 
adaptor protein inducing IFN-β (TRIF, also known as TICAM1) and TRIF-related 
adaptor molecule (TRAM, also known as TICAM2) (reviewed in ((82, 121)). 
MyD88 is used by all TLRs except TLR3 which signals through the adaptor 
molecule TRIF. Thus, TLR signaling can be largely classified as either MyD88-
dependent pathways or MyD88-independent /TRIF-dependent pathways. TLR4 
is the only TLR that uses all four adaptors and thus activates both the MyD88-
dependent and MyD88-independent pathways (Figure 1.2).   
 
ii. Retinoic acid-inducible gene-I (RIG-I)-like receptors 
RLRs are a family of DExD/H box RNA helicases that function as 
cytoplasmic sensors of viral RNA PAMPs. The RLRs include RIG-I, melanoma 
differentiation-associated gene (MDA-5) and laboratory of genetics and 
physiology 2 (LGP2) (reviewed in (99, 141)). RLRs are interferon-inducible 
proteins that are expressed at low concentrations in the resting cell and are 
greatly increased upon stimulation or activation (75, 174). Key structural domains 
include: caspase activation and recruitment domain (CARD), ATPase containing 
DEAD box helicase (DEAD helicase) and C-terminal domain (CTD) (Figure 1.3). 
The CTD of RIG-I and MDA-5 also encodes a repressor domain (RD). LGP2 
lacks the N-terminal CARD domains and is therefore unable to signal via the 
adaptor interferon-β promoter stimulator 1 (IPS-1). Currently, LGP2 is known to 
6
TIR domain 
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TRIF 
TRAM 
TLR2 or 
TLR5 
NF-κB NF-κB 
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IRF5 
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         or 
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late 
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IRF3 
 
NF-κB 
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Figure 1.2. Adaptor molecules of TLR signaling. MyD88, MyD88-adaptor-like (MAL, 
also known as TIRAP), TIR-domain containing adaptor protein inducing IFN-β (TRIF, also 
known as TICAM1) and TRIF-related adaptor molecule (TRAM, also known as TICAM2) 
are the four known signaling adaptors of TLRs.  Recognition by TLRs of its cognate ligand 
induces homo- or heterodimer formation of TLRs and the activation of signaling cascades 
leading to the activation of key transcription factors -- interferon regulatory factors (IRFs) 
and  nuclear factor κB (NF-κB).  
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 CARD           CARD           DEAD Helicase           RD; CTD 
 CARD           CARD           DEAD Helicase           RD; CTD 
DEAD Helicase                CTD 
 CARD       Pro                        TM 
RIG-I 
MDA-5 
LGP2 
IPS-1 
Figure 1.3. Simple representation of RLRs and their adaptor IPS-1. Retinoic-acid-
inducible gene I (RIG-I)-like receptors (RLRs) -- RIG-I, melanoma differentiation-associated 
gene 5 (MDA5) and laboratory of genetics and physiology 2 (LGP2). RIG-I and MDA5 
consist of caspase activation and recruitment domain (CARD), ATPase containing DEAD 
box helicase (DEAD helicase) and C-terminal domain (CTD). LGP2 consists only of DEAD 
helicase, C-terminal domain (CTD) and no repressor domain (RD). RLRs signal 
downstream via the adaptor, interferon (IFN) β-promoter stimulator 1 (IPS-1) that consists 
of CARD, a proline-rich region (Pro), and a transmembrane domain (TM) on its C terminus. 
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function as a regulator of RIG-I and MDA-5 signaling in an inhibitory or 
synergistic way, respectively (129, 137, 138, 166, 174). 
Although very similar in structure, the exact molecular signatures 
recognized by RIG-I and MDA5 are still not fully understood (6). RIG-I 
preferentially recognizes RNA sequences with 5’ triphosphorylated (5’ppp) ends, 
which serve in part to distinguish a non-self RNA PAMP (52). RIG-I can also bind 
to ssRNA and shows a preference for shorter RNA fragments compared to 
MDA-5 which preferentially recognizes long dsRNAs (greater than 1 kb in length) 
such as the high-molecular-weight polyinosinic:polycytidylic acid (poly I:C) 
fragments (80). 
Both RIG-I and MDA-5 interact downstream with the adaptor IPS-1 
through CARD repeats. IPS-1 is thought to be not directly involved in the 
signaling process but serves to orchestrate the molecular interactions which 
subsequently lead to the production of proinflammatory cytokines and type I IFN 
(Figure 1.4) (69). 
 
iii. Nucleotide-binding oligomerization domain (NOD)-like receptors 
NLRs comprise a large number of family member proteins that is 
characterized by the presence of conserved NOD motif (reviewed in (77)). The 
domain structure of NLR protein resembles the pro-apoptotic APAF1 and a 
subset of plant disease-resistance (R) genes (161). NLRs are defined by three 
characteristics: an N-terminal effector domain, a central nucleotide binding 
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Figure 1.4. RIG-I, MDA-5 and NLRP3 signaling. The double-stranded RNA (dsRNA) 
receptors retinoic-acid-inducible gene I (RIG-I) and melanoma differentiation-associated  gene 
5 (MDA5) are cytosolic receptors expressed in most cells. RIG-I and MDA5 signal through a 
common adaptor molecule,  interferon (IFN) β-promoter stimulator 1 (IPS-I), which is 
mitochondria associated.  Downstream signaling  of IPS-I leads to activation of transcription 
factors interferon-regulatory factor 7 (IRF7), IRF3 and nuclear factor κB (NF-κB) that induces 
the production of proinflammatory cytokines and type I interferons (IFNs).  Inactive NACHT-
LRR-Pyrin (PYD)-containing protein 3 (NLPR3) oligomerizes upon stimulation of an unknown 
mechanism. NLRP3 forms an inflammasome complex with proteins,  apoptosis-associated 
speck-like protein (ASC), Cardinal  and pro-caspase 1, leading to the activation of caspase-1, 
which mediates the processing of pro-IL-1β and pro-IL-18 (induced by TLR signaling) to 
mature IL-1β and IL-18, respectively.  FIIND, domain with function to find; FADD, fas-
associated death domain; NACHT, neuronal apoptosis inhibitory protein (NAIP), CIITA, HET-E 
and TP-1; LRR, leucine-rich repeat;  CARD, caspase activation and recruitment domains.  
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domain (NBD) and C-terminal repeats. N-terminal effector domains consist of 
either a PYD, CARD, baculovirus inhibitor of apoptosis repeat (BIR) domains or a 
transactivation domain. The NACHT-LRR-PYD-containing protein 3 (NLRP3, 
also known as NALP3, cryopyrin) is one of the best characterized NLRs. Upon 
activation, NLRP3 interacts with apoptosis-associated speck-like protein 
containing a CARD (ASC) that is essential for the binding and recruitment of 
pro-caspase 1 to form an inflammasome complex. This activates caspase 1 that 
mediates the cleaving of pro-IL-1β and pro-IL-18 into active IL-1β and IL-18, 
respectively (Figure 1.4) (69).  It is not yet known if NLRP3 directly detects 
nucleic acids or if NLRP3 is indirectly activated following nucleic acid detection 
by an unknown sensor that may interact with NLRP3. However, based on the 
broad range of NLRP3 activators, it is likely that NLRP3 may respond to a less 
specific stimulus such as cellular stress or alterations of host metabolites 
downstream of pathogen infection (171). 
 
B. RNA-sensing PRRs and RNA PAMPs 
Nucleic acid motifs are the main virus-derived PAMPs recognized by the 
PRRs of the innate immune system (Table 1.1). The focus of this dissertation is 
on RNA-sensing PRRs and the viral PAMPs that are detected during RNA virus 
infection. This includes TLR3, TLR7, TLR8, RIG-I, MDA-5 and NLRP3. Viral 
ssRNA is sensed by TLR7 and TLR8 in the endosomes and by RIG-I in the 
cytosol of many cell types. Viral dsRNA is recognized by RIG-I and MDA5 in the 
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cytosol, by TLR3 in the endosome of innate immune cells and by NLR, NLRP3. 
(Figures 1.4 and 1.5) (reviewed in (69)).  
 
C. dsRNA recognition: The Pre-TLR/PRR Era 
 Recognition of extracellular or cytoplasmic dsRNA is thought to occur 
primarily via two different classes of PRRs – through TLRs (TLR3) and RLRs 
(RIG-I and MDA-5), respectively. However, there is a third classic molecule, 
recently classified in reviews as also a PRR for cytoplasmic dsRNA -- protein 
kinase R (PKR) (65, 113). PKR is a 68-kDa cytoplasmic dsRNA-dependent 
serine/threonine kinase. Upon binding of dsRNA, PKR is activated and 
undergoes dimerization and autophosphorylation. PKR phosphorylates its 
physiological substrate, eukaryotic initiation factor 2α (eIF-2α), resulting in the 
block of translation of both viral and cellular RNAs (reviewed in (33)). Previous 
studies demonstrated that PKR is required for IFN production in bone marrow-
derived DCs, mouse embryonic fibroblasts and in the recognition of particular 
viruses (25, 35). PKR has also been implicated to enhance the induction of IFN-β 
mediated by cytoplasmic RNA PRRs (109). Though PKR is firmly established to 
play a central role in IFN-dependent antiviral actions, it is likely that PKR, as a 
PRR, plays a much broader function in the initiation and mounting of adaptive 
immune responses.  
 
 
12
Figure 1.5. TLR7/TLR8 and TLR3 signaling. Endosomal Toll-like receptor 7 (TLR7), TLR8 
and TLR3 recognize RNA ligands. TLR7 and TLR8 recognize single-stranded RNA (ssRNA) 
while  double-stranded RNA (dsRNA) is recognized by TLR3. TLR7 and TLR8 signal through 
the adaptor protein, MyD88, which leads to the downstream activation of transcription factors 
interferon-regulatory factor 7 (IRF7) and nuclear factor κB (NF-κB). By contrast, TLR3 signals 
through the adaptor TRIF for the activation of IRF3 and NF-κB. TLR7, TLR8 and TLR3 signaling 
also activate the mitogen-activated protein kinases (MAPKs) pathway. Overall, these pathways 
potently induces the production of proinflammatory cytokines and type I interferons (IFNs). 
TRAF, tumor-necrosis factor (TNF)-receptor-associated factor; BTK, Bruton’s tyrosine kinase; 
IRAK, interleukin-1 receptor-associated kinase; IκB, inhibitor of NF-κB; TBK1, TANK-binding 
kinase 1; IKKε, inhibitor of NF-κB kinase ε. 
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D. Expression of RNA-sensing PRRs on different cell types 
PRRs have evolved to efficiently recognize PAMPs and this includes 
specific expression of PRRs in specific cell types (reviewed in (3, 82, 83)). RIG-I 
and MDA-5 are expressed in most cell types and are upregulated upon 
stimulation or activation. Most antigen presenting cells (APCs) express TLR3, 
TLR7 and TLR8. TLR3 is detected in conventional DCs, macrophages and also 
in non-immune cells such as fibroblasts and epithelial cells. TLR7 is highly 
expressed in plasmacytoid DCs (pDCs), a DC subset that can secrete vast 
amounts of type I IFN in response to viral infection. TLR8 is also expressed in 
various tissues with the highest expression in monocytes. CD4+ and CD8+ T-
cells also express these RNA-sensing TLRs (53, 175). NLRP3 is expressed in T-
cells (92). The expression of these different RNA-sensing PRRs in different cell 
types suggests sophisticated mechanisms for detecting RNA viruses. Previous 
studies have mainly focused on RNA-sensing PRR activation in APCs. 
Delineating the role of PRR activation within specific cell types, such as in T-
cells, would further advance our current knowledge in the contribution of RNA-
sensing PRRs in innate and adaptive immune responses. 
 
E. RNA PAMPs as adjuvants 
Adjuvants are important in eliciting robust protective immune responses 
from vaccines but many of their underlying mechanisms are yet to be fully 
elucidated (51). Vaccine adjuvants mainly target professional antigen-presenting 
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cells (APCs) such as dendritic cells and activate innate immunity through pattern 
recognition receptor (PRR) pathways (51, 108). For protection against most 
viruses and intracellular pathogens, adjuvants that stimulate CD4+ T helper type 
1 (Th1) responses are desirable (67). CD4+ T-cell help is known to be required 
for optimizing B-cell and CD8+ T-cell responses, and can also provide protection 
through direct cytotoxic effector functions (116, 178). Unfortunately, potent CD4+ 
T-cell adjuvant activity in humans has often been associated with unacceptable 
toxicity (e.g. complete Freund’s adjuvant (68)). Therefore, one of the major 
challenges in adjuvant research has been to gain CD4+ Th1 stimulatory activity 
while minimizing potential toxicity. 
RNA-like immune response modifiers (IRMs) can skew acquired immune 
responses towards a Th1 phenotype while suppressing Th2 responses (98, 149, 
163, 165). Among these RNA-like IRMs, resiquimod (R-848) and poly I:C are 
being evaluated as T-cell adjuvants for vaccine development (98, 130, 132, 176). 
R-848 is a synthetic imidazoquinoline-like molecule that triggers cellular 
responses via the endosomal TLR7 and TLR8 and MyD88-dependent signaling 
(24, 48). Poly I:C is a synthetic analog of viral dsRNA that activates 
MyD88-independent immune responses through TLR3/TRIF and the 
MDA5/IPS-1) signaling pathways (Figures 1.4 and 1.5) (106, 168).   
These RNA-sensing PRRs and signaling pathways are present in APCs 
and CD4+ T-cells (71, 83). RNA-like IRM activation of MyD88-dependent and 
MyD88-independent signaling pathways can induce a broad range of cell-specific 
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responses, including NF-ƙB activation, type I interferon (IFN) and 
pro-inflammatory cytokine production, and co-stimulatory molecule upregulation 
(83, 149, 163). The ability of RNA-like adjuvants to stimulate CD4+ Th1 
responses likely depends on a combination of key signaling pathways in APCs 
and CD4+ T-cells. A better understanding of the critical signaling pathways by 
which RNA-like IRMs stimulate CD4+ Th1 responses will help in the 
establishment of effective strategies in the generation of rationally designed 
vaccine adjuvants.  
 
F.  Influenza A virus recognition by RNA-sensing PRRs 
 Influenza A virus (IAV) is a negative-sense single-stranded segmented 
RNA virus of the orthomyxovirus family. IAV can be recognized predominantly by 
RNA-sensing PRRs TLR3,TLR7, RIG-I and NLRP3 (Figure 1.6) (reviewed in 
(57)). RIG-I recognizes the 5’ppp of IAV genomic RNA in IAV-infected fibroblasts 
(127). TLR7 recognizes the IAV genomic RNA in the endosome of pDCs and 
helped identify ssRNA as a ligand for TLR7 (24). TLR3 has also been involved in 
the immune responses of lung epithelial cells to IAV (42). The NLRP3 
inflammasome can also be activated during IAV infection (78, 124, 158). The 
NLRP3 inflammasome detects IAV infection by sensing disturbances in 
intracellular ionic concentrations induced by the IAV M2 protein (59). Further 
investigation is needed to elucidate the role of RNA-sensing PRRs in mediating 
host innate and adaptive immune responses to IAV.  
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Figure 1.6. Recognition of Influenza A virus (IAV) by RNA-sensing PRRs. The TLR, RLR 
and NLR pathways are able to target multiple steps in the viral life cycle. The viral genome and 
replicative intermediates of IAV are recognized intracellularly, either in the endosome or cytosol 
by RNA-sensing PRRs including  by TLR3, TLR7/8, RIG-I and NLRP3. 
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 G.  Adaptive Immune Response to Influenza A virus 
 Both cellular (CD8+ and CD4+ T-cells) and humoral immunity contribute 
significantly to the clearance of influenza viruses and protection against IAV 
infection. 
 i. Role of CD8+ T-cells 
 CD8+ T-cells play a major role in the control of primary and secondary IAV 
infections. Three to four days after intranasal infection, activation and the 
expansion of naïve CD8+ T-cells occur in the draining mediastinal lymph nodes. 
Five to seven days after infection, the influenza-specific CD8+ T-cells migrate to 
the lungs and infected airway epithelium where they exert effector functions, 
lysing infected target cells and producing antiviral cytokines. Influenza-specific 
CD8+ T-cells recognize multiple viral epitopes on target cells and APCs. In 
C57BL/6J (B6) (H2Db) mice, the dominant CD8+ T-cell epitopes identified are on 
the nucleoprotein (NP)366-374 (162) and polymerase (PA)224-233 (10). A small 
proportion of influenza-specific CD8+ T-cells recognize other viral proteins 
(reviewed in (151)). Viral clearance is observed 10 days after primary IAV 
infection which coincides with the peak of CD8+ T-cell responses to NP366-374 and 
PA224-233 (86, 150). IAV-specific CD8+ T-cell responses to a subsequent infection 
are detected around 2 days faster than the primary response with more efficient 
clearance of IAV (reviewed in (91)). 
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 ii. Role of CD4+ T-cells 
 The elimination of the IAV from the respiratory tract is mediated by CD8+ 
T-cells and B-cells, however, optimal influenza-specific  Ab production by B cells 
is dependent on CD4+ T-cell help (155). Though IAV-specific Abs can be 
generated without CD4+ T-cells, Ab production is more effective and vigorous 
following interactions between B cells and CD4+ T-cells (96, 139). For CD8+ T-
cells, the priming of naïve CD8+ T-cells is dependent on CD4+ T helper cell 
activity (12) and is necessary for the maintenance of protective CD8+ memory T-
cell populations (73). 
Memory CD4+ T-cells also enhance the production of innate inflammatory 
cytokines and chemokines in the lung during influenza infection that leads to 
early control of IAV (154). Recently, a study on infected human subjects found 
that the number of pre-existing influenza-specific CD4+ T-cells were inversely 
related to the severity of illness after challenge and suggest that activation of 
long-lived cross-protective CD4+ T-cells should be one of the goals of influenza 
vaccine development (87, 172)  
iii. Role of humoral immunity 
Antibodies play a substantial role in terminating influenza virus infections. 
Protective antibodies are directed against hemagglutinin (HA) and neuraminidase 
(NA) which are found on the external surface of the influenza virus. The 
importance of humoral responses has been clearly demonstrated in severe 
combined immunodeficiency (SCID) mice that can be protected by passive 
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administration of HA-specific antibodies (123).  The main antibody isotypes in the 
influenza-specific humoral response are IgA, IgM and IgG. Mucosal or secretory 
IgA affords local protection from infection of airway epithelial cells. Complement-
mediated neutralization of influenza can be mediated by IgM Ab while serum IgG 
predominantly transudates into the respiratory tract and contributes to long-lived 
protection (117) (reviewed in (91)). 
 
H. Heterosubtypic Immunity to IAV 
Heterosubtypic immunity to IAV was first demonstrated in 1965 (144). 
Heterosubtypic immunity is defined as immunity generated by a given IAV 
subtype or its antigens that protects against challenge with other IAV subtypes 
(e.g. immunity to H1N1 protecting against infection with H3N2) (reviewed in (38)). 
Using two IAV subtypes with different HA and NA proteins allows examination of 
primary IAV-specific responses and facilitates the detailed dissection of 
secondary T-cell responses without the difficulties associated with cross-
neutralizing antibodies (151). Heterosubtypic immunity induced does not prevent 
infection like the neutralizing antibodies against the viral gylcoproteins HA and 
NA (14). However, heterosubtypic immunity does confer a certain degree of 
protection, reduces mortality otherwise caused by IAV infection and has been 
shown to be long lasting (38). Understanding the mechanism of hetrosubtypic 
immunity has been the focus of numerous studies. It has been demonstrated in 
mice that virus-specific CD4+ T-cells, CD8+ T-cells, virus-specific antibodies and 
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B-cells contribute to heterosubtypic immunity (38). CD8+ T-cells predominantly 
recognize cross-reactive epitopes found in conserved proteins such as the NP 
and matrix (M) protein of IAV. CD8+ T-cells are therefore able to recognize and 
kill virus-infected cells based on MHC class I restricted presentation of conserved 
IAV epitopes (159). 
The role of CD4+ T-cells in heterosubtypic immunity to IAV has been 
studied less extensively than CD8+ T-cells and remains controversial. CD4+ T-
cells are needed for antibody class switching and B cell somatic hypermutation 
and are therefore important in the development of effective anti-IAV antibody 
responses(159).  
Though other effector immune cells could potentially contribute to 
heterosubtypic immunity to IAV (i.e. NKT cells and γδ T-cells), it is evident that T 
cells can mediate protective immunity. Elucidation and a better understanding of 
the mechanisms involved in the heterosubtypic immunity to IAV would contribute 
towards the development of vaccines that confer protection against all IAV 
subtypes. 
 
I.  Thesis Objectives 
 The overall goal of this thesis is to delineate the role of RNA-sensing 
pattern recognition receptors in the shaping and modulation of T-cell immune 
responses to RNA viruses. We hypothesize that the activation of the RNA-
sensing pattern recognition receptor pathways in T-cells and in antigen 
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presenting cells are crucial in the development of virus-specific T-cell 
immune responses.  
 
This thesis is presented in three parts: 
 
Chapter III: Direct co-stimulatory effects of RNA PAMPs on conventional 
CD4+ T-cells 
Aim: Delineate the signaling pathways activated by RNA PAMPs directly on 
conventional CD4 T-cells 
Hypothesis: RNA PAMPs can act directly on CD4 T-cells and modulate their 
function and phenotype 
 
Chapter IV: Critical RNA-sensing PRR pathways are activated by RNA 
PAMPs/adjuvants that drive Th1 CD4+ T-cell responses in cDC/CD4+ T-cell 
interactions 
Aim: Delineate the signaling pathways activated by RNA PAMPs that drive Th1 
CD4+ T-cell responses in cDC/CD4+ T-cell interactions 
Hypothesis: RNA PAMP activation of TLR7MyD88 signaling in cDC augments 
alloreactive CD4+ Th1 responses through type I IFN and early IL-1α & IL-1β 
production and signaling. 
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Chapter V: Contributions of RNA-sensing PRR pathways on  
Th1 responses to IAV infection 
Aim: Delineate the contributions of RNA-sensing PRR pathways on Th1 
responses to an RNA virus 
Hypothesis:  MyD88-signaling is essential in the RNA-sensing pathways 
activated in the development of heterosubtypic immunity to Influenza A. 
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CHAPTER II: 
MATERIALS AND METHODS 
 
A. Mice 
C57BL/6J (B6), BALB/cJ, B6.C-H2d/bByJ (B6.H2d), F1 and F2 of 
C57BL/6J x 129S1/SvlmJ mice were purchased from The Jackson Laboratory 
(Maine, USA).  MyD88-/-, TLR7-/-, TLR3-/- , IL-1R-/-, IL-18R-/-, MAVS-/-, MDA5-/- , 
NLRP3-/- , ASC-/-, TRIF-/- , MAVS/TRIF-/- and type I IFN receptor-/- (IFNAR-/-) mice 
were provided by Drs. R. Finberg, E. Kurt-Jones and K. Fitzgerald (University of 
Massachusetts Medical School, Worcester, MA). IL-1α-/-, IL-1β-/- and IL-1αβ-/- 
mice were provided by Drs. K. Rock and H. Kono (University of Massachusetts 
Medical School). The genetically modified knockout mice were backcrossed eight 
or more generations onto the B6 background and were then intercrossed to 
obtain the knockout genotypes.  For mice not fully backcrossed onto the B6 
background, F1 or F2 of C57BL/6J x 129S1/SvlmJ were used as wild type 
controls. The knockout genotypes were confirmed by PCR genotyping. All animal 
procedures were conducted in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by the University of Massachusetts Medical 
School Animal Care and Use Committee (Protocol A-1884).  
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B. Reagents /Antibodies 
 Resiquimod (R-848) was purchased from 3M Pharmaceuticals (St. Paul, 
MN), polyinosinic:polycytidylic acid (poly I:C) was purchased from Alexis 
Biochemicals (San Diego, CA). For the anti-CD3 stimulation experiments: poly 
(dT), CL075 and 2-aminopurine were purchased from Invivogen (San Diego, 
CA); RNA-dependent protein kinase inhibitor (PKR inhibitor) and RNA-dependent 
protein kinase inhibitor negative control were purchased from Calbiochem (San 
Diego, CA). 
Antibodies used in all experiments were purchased from BD Biosciences 
(San Jose, CA) and eBiosciences (San Diego, CA). The antibodies/markers used 
in experiments are listed in Table 2.1. For experiments where anti-CD3 and anti-
CD28 were used, functional grade purified anti-mouse CD3ε (clone 1 45-2C11) 
and functional grade purified anti-mouse CD28 (clone 37.51) were purchased 
from eBiosciences.  
For the add-in and blocking MLR experiments, the following reagents were 
used: universal Type I IFN (PBL Biomedical Laboratories, Piscataway, NJ), 
mouse rIL-1α, rIL-1β and soluble IL-1 receptor antagonist (sIL-1Ra) (R & D 
Systems, Minneapolis, MN), AnakinraTM (sIL-1R antagonist) (Amgen, Thousand 
Oaks, CA), anti-mouse IFN α/β receptor IgG1 (anti-IFNAR) (Leinco, St. Louis, 
MO), and purified mouse IgG1 isotype control (BD Biosciences). 
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Isolation of 
mouse CD4+ T-
cells 
Isolation of 
human CD4+ 
T-cells 
cDC sorting 
for MLR MLR ICS IAV ICS 
Tetramer 
analysis 
CD3-Pacific 
Blue/V450* CD4 - FITC CD11c - FITC 
CD3-Pacific 
Blue/V450 
CD3-Pacific 
Blue/V450 
CD3 - 
PerCPCy5.5 
CD4 - FITC 
CD8 - 
PerCPCy5.5 CD11b - PE 
CD4 - 
PerCPCy5.5 
CD4 - 
PerCPCy5.5 CD8 - Alexa 647 
CD8 - 
PerCPCy5.5 TCRγδ - PE 
CD45R - 
PerCP TCRβ - PE CD8 - PE CD44 - FITC 
TCRγδ - PE CD56 - APC   DX5 - PECy7 DX5 - PECy7 
CD8 tetramer - 
PE 
DX5 - APC     IFN-γ - APC IFN-γ - APC   
  
  
  
TNFα - Alexa 
700 
TNFα - Alexa 
700   
      IL-2 - FITC IL-2 - FITC   
      LDA LDA   
Table 2.1. List of antibodies used. 
* For anti-CD3 stimulation experiments, cells were not surface stained with anti-CD3 antibodies. 
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C. Isolation of CD4+ T-cells 
 Murine conventional CD4+ T-cells were isolated from splenocytes by 
magnetic bead enrichment for CD4+ T-cells (MACS, Miltenyi Biotec, Auburn, CA) 
followed by flow cytometry sorting for the CD3+CD4+CD8-DX5-TCRβ+ 
lymphocytes. Analysis of the CD4+ T-cells after FACS consistently demonstrated 
≥99% purity. The sorted CD4+ T-cells were at least 80% CD62Lhi indicating 
mostly naïve CD4+ T-cells. 
 Human CD4+ T-cells were isolated from blood samples of healthy adult 
volunteers. PBMCs were purified by Histopaque ® (Sigma, St. Loius, MO) 
density gradient centrifugation. Blood was carefully layered onto Histopaque® 
and centrifuged for 30 min at 1,400 rpm with no brake. The interface with the 
PBMCs was collected and washed before magnetic bead enrichment for CD4+ 
T-cells (MACS). The cells were then surface stained with antibodies for flow 
cytometry sorting (CD4+CD8-TCRγδ-CD56-). 
 
D. Anti-CD3 stimulation of CD4+ T-cells 
Purified murine and human CD4+ T-cells (2 x 105 cells/ well) were cultured 
in anti-CD3 coated 96-well flat-bottom plates. Plates were coated with 0 to 
8 µg/ml concentrations of anti-CD3 in PBS overnight. The murine TLR7 agonist, 
R-848, and the TLR3 and MDA5 agonist, poly I:C, were added at final 
concentrations of 20 µM and 100 µg/ml, respectively. These agonist 
concentrations produced maximal T-cell responses in preliminary experiments. 
27
Anti-CD28 (1.5 µg/ml) was also added as positive control. After 3 days, 
cell-free culture supernatants were collected for IFN-γ ELISA. 
In some of the anti-CD3 stimulation experiments the following were 
also added: 3µM and 6µM poly (dT) (TLR7/modulator), 50ng/ml and 
100ng/ml CL075 (TLR8/7 IRM), 2mM 2-aminopurine (PKR inhibitor), 10µM 
PKR inhibitor and 10µM PKR inhibitor negative control. The 
concentrations of these reagents were based on concentrations reported 
in literature. 
 
E. Enzyme-linked immunosorbent assay 
Cell culture supernatants were collected and analyzed for human 
IFN-γ, mouse IFN-γ, IL-1α and IL-1β by enzyme-linked immunosorbent 
assay (ELISA) according to the manufacturer’s protocol (BD Biosciences, 
San Jose, CA). The ELISA plates were developed using 3,3’,5,5’-
tetramethylbenzidine (TMB) (KPL, Gaithersburg, MD), and the reactions 
were stopped with 2N sulfuric acid. Optical densities were read at 450nm 
using a Spectra MAX microplate reader and analyzed with Softmax® Pro 
5 Software (Molecular Devices, Sunnyvale, CA). 
 
F. CFSE staining 
FACS-sorted CD4+ T-cells were washed and resuspended at 
107cells/ml in PBS with 2% FBS and 1mM EDTA. CFSE was added at 
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1µM final concentration and incubated for 15 min at 30oC. The staining reaction 
was stopped by washing twice with RPMI medium with 10% FBS. 
 
G. Generation and isolation of conventional DCs 
Bone-marrow derived conventional dendritic cells (cDCs) were prepared 
as described previously (167). In brief, bone marrow cells were cultured in RPMI 
supplemented with 10% FBS, 50 µM 2-mercaptoethanol and 20 ng/ml 
recombinant fms-related tyrosine kinase 3 ligand (rFlt3L,R&D Systems) for 7 
days. Bone-marrow derived dendritic cells were scraped off the culture dish, 
washed with PBS and then stained with fluorochrome-conjugated antibodies for 
fluorescence-activated cell sorting (FACS). cDCs (CD11c+CD11b+CD45R-/lo) 
were isolated by sorting on a BD FACSAria flow cytometer (BD Biosciences). 
 
H. Mixed Leukocyte Reactions 
FACS-sorted cDCs (2 x 104 cells) and CD4+ T cells (2 x 105 cells) were 
co-cultured for six days in allogeneic and MHC congenic mixed leukocyte 
reactions (MLRs). Initial experiments were performed using cells from wild-type 
B6 (H2b) and BALB/c (H2d) mice to induce an allogeneic response. We 
subsequently switched to using MHC congenic H2d mice on the B6 background, 
B6.C-H2d/bByJ (B6.H2d) in order to exclude B6 and BALB/c strain differences 
(97). No apparent differences between the allogeneic and MHC congenic 
systems were observed. The murine TLR7 agonist, R-848, and the TLR3 and 
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MDA5 agonist, poly I:C, were added to MLRs at final concentrations of 20 µM 
and 100 µg/ml, respectively. These agonist concentrations produced maximal T-
cell responses in preliminary experiments. After six days, cell-free culture 
supernatants were collected for ELISA and cells were collected for ICS analysis.  
 
I. Addition of type I IFN and IL-1 and blockade of type I IFN and IL-1α/β 
signaling 
With concentrations based on previously published literature, universal 
type I IFN (200U/ml) (39) and rIL-1α and rIL-1β (125 pg/ml each) (119) were 
added in some MHC congenic MLRs. To block endogenous type I IFN and IL-1 
signaling, anti-mouse IFN α/β receptor IgG1 (5 µg/ml) (148) and AnakinraTM (10 
µg/ml) (79) or recombinant mouse sIL-1Ra (1 µg/ml) (169) were added to R-848 
stimulated MHC congenic MLRs. Purified mouse IgG1 isotype antibody (5 µg/ml) 
was used as a control. The concentrations used in the addition and blocking 
experiments were based on concentrations reported in literature. After six days, 
cell-free culture supernatants were collected for ELISA and cells were collected 
for ICS. 
 
J. Intracellular cytokine staining 
i. ICS for MLRs 
IFN-γ and TNF-α-secreting CD4+ T-cells were quantified by intracellular 
cytokine staining (ICS) assay. After 6 days in culture, co-cultured cDCs and 
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CD4+ T-cells in MLRs were collected, washed in RPMI media with 10% FBS and 
then cultured for 5 to 6 hours without restimulation in the presence of Brefeldin A 
(BD Biosciences, San Jose, CA). Cells were stained with surface antibodies, and 
permeabilized with Cytofix/Cytoperm (BD Biosciences, San Jose, CA) before 
intracellular staining with antibodies and fixation. CD4+ T-cells were analyzed 
using a BD FACSAria cytometer. LIVE/DEAD® Fixable Dead Cell Stain Kit 
(Invitrogen, Carlsbad, CA) was used to exclude nonviable cells from analysis. 
IFN-γ or TNFα secreting CD4+ and CD8+ T-cells were identified as 
LDA-/CD3+/CD4+ or CD8+/ IFN-γ+ or TNFα+ cells (Figure 2.1). Data was analyzed 
using FlowJo software (Treestar, Ashland, OR). 
ii. ICS for influenza A virus-specific CD4+ and CD8+ T-cells 
The spleen & lung cell suspensions were washed with media, and then 
stimulated for 6 hours with immunodominant influenza A virus (IAV) internal 
protein CD4+ or CD8+ T-cell peptides (CD4+ T-cell epitope -- nucleoprotein 
(NP)311-325, AnaSpec, Inc., San Diego, CA) (CD8+ T-cell epitopes -- NP366-374 and 
polymerase (PA)224-233, AnaSpec, Inc.) (9, 19, 162).  The peptide stimulations 
(10µg/ml each) were done in the presence of 1µl Brefeldin A (BD Biosciences).  
This was followed by staining as described in ICS for MLRs.  
 
K. Luminex analysis 
31
Figure 2.1. Intracellular cytokine staining for influenza A virus (IAV)-specific T-
cells. Interferon-γ (IFN-γ) or tumor necrosis factor-α (TNFα)-secreting CD4+ and CD8+ 
T-cells were gated as live/dead aqua (LDA)-/CD3+/CD4+ or CD8+ lymphocytes. Spleen 
and lung cell suspensions were stimulated for 6 hours with MHC class I or II-restricted 
IAV peptides, as described in previous figures, in the presence of Brefeldin A. One 
representative example is shown. 
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Cell culture supernatants collected from mouse and human anti-
CD3 stimulation experiments were sent for Luminex® multiplex cytokine 
analyses to the Luminex Core of the Baylor Institute for Immunology 
Research. 
 
L. Quantitative RT-PCR 
IL-1α, IL-1β and IFN-β mRNA expression were determined using RNeasy 
Plus Mini Kit for RNA extraction (Qiagen, Valencia, CA) and TaqMan RNA-to-CT 
1-step kit for RT-PCR (Applied Biosystems, Carlsbad, CA). All primers and 
probes used were TaqMan Pre-Developed Assay Reagents for Gene Expression 
(Applied Biosystems, Carlsbad, CA; IL-1α - Mm00439620_m1, IL-1β - 
Mm01336189_m1 and IFN-β - Mm00439546_s1). Levels of gene expression 
were normalized to β-actin for each sample. Fold increase in gene expression 
was determined using the ΔΔCT method. Samples were run in triplicates and the 
results are presented as linear-fold changes in gene expression. 
 
M. IL-1β cleavage assay 
cDCs (>90% purity) were cultured in serum-free medium. To promote 
maturation and release of IL-1β, adenosine-5'-triphosphate (ATP, 5mM, Sigma, 
St. Louis, MO) was added one hour prior to harvesting supernatants. As a 
positive control, cDCs were primed with lipopolysaccharide (200 ng/ml) for 3 
hours prior to stimulation with Nigericin (10µM, Sigma, St. Louis, MO).  Cell 
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culture supernatants were collected after six hours and stored at -20oC until used 
in Western blot assay. Proteins were precipitated from supernatants by adding 
an equal volume of methanol and 0.25 volume of chloroform, mixed, and 
centrifuged at 16,100xg at room temperature for 10 min. The upper phase was 
discarded without disrupting the intermediate phase before adding another equal 
volume of methanol. The resulting mixture was mixed and then centrifuged at 
16,100xg for 5 minutes. The liquid phase was decanted and the protein pellet 
was air dried for 3 to 5 min. Dried pellets were resuspended in Laemmli’s SDS 
sample buffer, heated at 100oC for 5 minutes, and then loaded into 4-20% 
precast polyacrylamide gels (Bio-RAD, Hercules, CA). Proteins were transferred 
to Hybond-P PVDF membranes (GE Healthcare, Pittsburgh, PA) and a goat 
anti-mouse IL-1β antibody (R&D Systems, Minneapolis, MN) was used to detect 
IL-1β.  
 
N. Influenza A Viruses 
Purified influenza A viruses (IAV) influenza A/Puerto Rico/8/34 H1N1 
(PR/8) and influenza A/HK/X31 H3N2 (HK/X31) stocks were purchased from 
Charles River (Wilmington, MA).  The HK/X31 virus is a laboratory reassortant 
that contains the same internal proteins as PR/8 (88). 
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O. Heterosubtypic  IAV infection model 
Primary IAV infections were carried out by intranasal infection of 
naïve mice with 10 plaque forming units (pfu) of the PR/8 virus (a 
sublethal dose). After 21 days, the mice were challenged with 104 pfu of 
the HK/X31 virus by intranasal infection (a sublethal dose).  7 days later, 
the mice were sacrificed and T-cell and Ab responses to immunodominant 
internal PR/8 proteins were examined. For homotypic IAV infections, 
primary IAV infections were carried out by intranasal infection of naïve 
mice with 10 pfu PR/8 virus and challenged 21 days later with 2x105 pfu 
PR/8. 
 
P. Spleen and lung sample preparation for ICS analysis 
IFN-γ and TNFα-secreting CD4+ and CD8+ T-cells in mouse 
spleens and lungs were identified by ICS.  Spleens were collected and 
homogenized by passing through 40 μm nylon strainers and lysing RBCs 
with ammonium chloride in Tris-HCl buffer (Sigma, St. Louis, MO).  Lungs 
were treated with liberase enzyme solution (0.14 U/ml, Roche, 
Indianapolis, IN) and DNAse I (2,000 U/ml, New England BioLabs Inc., 
Ipswich, MA) for 45 min at 37oC prior to homogenization. The spleen & 
lung cell suspensions were washed with media, stimulated with 10µg/ml 
CD4+ or CD8+ T-cell peptides (CD4+ T-cell epitope -- NP311-325; CD8+ T-
cell epitopes -- NP366-374 and  PA224-233) and then stained for ICS. 
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 Q. MHC class I tetramer staining 
MHC Class I peptide tetramers (PR/8 IAV nucleoprotein (NP)366-374/Db) 
were generated by the NIH Tetramer Facility (Atlanta, GA). Tetramer staining 
was performed for 30 min, on ice, followed by staining for CD8+ T-cells. LDA was 
used to exclude nonviable cells from analysis. 
 
R. IAV NP protein-specific IgG2c, IgG1 and total IgG serum ELISA 
Sera from IAV infected mice were obtained 21 days after primary infection 
and 7 days after secondary infection.  Anti-NP specific antibodies were 
determined by ELISA.  Briefly, 1 µg/ml of purified recombinant IAV PR/8 NP 
(Imgenex, San Diego, CA) was used as antigen on 96-well flat-bottomed 
microtiter plates (Thermo Scientific, Rochester, NY) coated overnight at 4oC.  
Serum samples were serially diluted (4-fold, starting dilution 1:1,000) in 2% fetal 
bovine serum in PBS (Figure 2.2). Diluted sera were added to plates and 
incubated for 2 hours at room temperature. Then, horseradish peroxidase (HRP)-
conjugated anti-mouse total IgG, IgG2c and IgG1 (dilution 1:2,000) were used as 
detecting antibodies (Southern Biotech, Birmingham, AL). The ELISA plates were 
developed using TMB, and the reactions were stopped with 2N sulfuric acid.  
Relative antibody concentrations were determined using optical 
spectrophotometer readings at 450nm using a Spectra MAX microplate reader 
and analyzed with Softmax® Pro 5 Software (Molecular Devices, Sunnyvale, 
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Figure 2.2. Serial dilution of naïve and IAV immune sera  for NP-specific ELISA. 
Representative sample curve of serially diluted naïve and immune sera.  Samples 
were diluted 4-fold (1:4,000 to 1: 16,384,000) and detected for total IgG, IgG2c and 
IgG1. Titers for anti-NP antibodies were defined as the reciprocal of the serum dilution 
that gave 50% binding in the linear range of the assay. 
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CA). The titers for anti-NP total IgG, IgG2c and IgG1 antibodies were defined as 
the reciprocal of the serum dilution that gave 50% binding in the linear range of 
the assay. 
 
S. Statistical Analysis 
Statistical analysis was done using GraphPad Prism Software version 
5.04 (GraphPad, San Diego, CA).  Comparisons between two normally 
distributed variables were performed using the unpaired Student’s t-test. 
Comparisons between two non-normally distributed variables were performed 
using the nonparametric Mann Whitney U test.  A difference was considered 
significant if the p-value was < 0.05 
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CHAPTER III 
DIRECT CO-STIMULATORY EFFECTS OF RNA PAMPS  
ON CONVENTIONAL CD4+ T-CELLS 
 
A. Introduction 
PRRs are expressed in various cell types and at greatly varying 
expression levels. In addition to DC and monocytes, TLRs are expressed on 
B-cells, NK cells, and T-cells (53, 71). Recent studies suggested that different 
TLRs are expressed on different T-cell subsets (17, 53, 175). The expression of 
TLRs on T-cells could allow TLR ligands to directly influence T-cell function. 
Several studies have examined the direct influence of TLR signaling on T-cells 
(17, 53, 61, 134).  PAMPs can directly promote CD4+ T-cell activation, survival, 
proliferation, cytokine production and affect memory CD4+ T-cell phenotypes (17, 
34, 147).  In this chapter, we focused on RNA PAMPs and their direct co-
stimulatory effects on conventional CD4+ T-cells. CD4+ T-cells were isolated 
from mouse spleens and human PBMCs. The CD4+ T-cells were enriched by 
MACS and then purified by flow cytomtery in order to eliminate the potential 
effects of bystander cells (e.g. natural killer cells, γδ T-cells). We used gene-
deficient mice to delineate the RNA-sensing PRR pathways that are activated on 
CD4+ T-cells. FACS-sorted CD4+ T-cells were cultured on anti-CD3 coated 
plates in the presence of RNA-like IRMs R-848 and poly I:C for 3 days. We 
assessed IFN-γ levels in cell culture supernatants by ELISA and Th1 and Th2 
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cytokines by Luminex ® as measures of the direct co-stimulatory effects of the 
RNA-like IRMs. 
  
B. RNA PAMPs can act directly on CD4+ T-cells and modulate their 
functions and phenotype 
In initial experiments, different concentrations of anti-CD3 (0 to 8 µg/ml) 
were used to stimulate mouse CD4+ T- cells. The co-stimulatory effects of the 
TLR7-MyD88-dependent IRM R-848 and the MyD88-independent IRM poly I:C 
were assessed. We observed an increase in IFN-γ levels with poly I:C and 
minimal direct co-stimulatory effect with R-848 (Figure 3.1.) Succeeding 
experiments were done using 6 µg/ml and 8 µg/ml anti-CD3 where maximal 
direct co-stimulatory effects were observed. 
Higher concentrations of Th1 cytokines (IFN-γ, TNFα and IL-2) and Th2 
cytokines (IL-4, IL-13 and IL-10) were observed with poly I:C-stimulated mouse 
CD4+ T-cells compared to R-848-stimulated mouse CD4+ T-cells using 
Luminex® analyses (Figure 3.2.). CD4+ T-cells were also stained with CFSE to 
determine whether CD4+ T-cells proliferated during the 3-day culture. 
Proliferation was observed in poly I:C-stimulated mouse CD4+ T-cells while 
proliferation observed in R-848-stimulated CD4+ T-cells was comparable to 
unstimulated mouse CD4+ T-cells (Figure 3.3).  
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Figure 3.1. R-848 treatment has minimal direct co-stimulatory effect compared to 
poly I:C in mouse CD4+ T-cells. FACS-sorted mouse CD4+ T-cells were cultured  for 
3 days in anti-CD3 coated plates in the presence of R-848 or poly I:C. Anti-CD28 was 
added as positive control. IFN-γ production in anti-CD3 stimulated (0 to 8µg/ml) CD4+ 
T-cells in the presence of R-848 and poly I:C. One representative experiment of at 
least three independent experiments is shown. 
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Figure 3.2. Luminex analysis of effector cytokines in anti-CD3 stimulated mouse 
CD4+ T-cells in response to R-848 or poly I:C. Cell culture supernatants were 
collected 3 days post stimulation of mouse CD4+ T-cells with anti-CD3 (8 µg/ml) 
Supernatants were analyzed by Luminex®. Replicates were pooled into one sample 
for analysis. One representative experiment of at least two independent experiments is 
shown. 
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Figure 3.3. Poly I:C treatment induces CD4+ T-cells to proliferate. FACS-sorted 
mouse CD4+ T-cells were stained with CFSE and cultured  for 3 days in 6 µg/ml anti-
CD3 coated plates in the presence of R-848 (20 µM) or poly I:C (100 µg/ml). Anti-
CD28 (1.5 µg/ml) was added as positive control (n=1). Cell proliferation was assayed 
by flow cytometry as shown by the shifting of CFSE peaks to the left. 
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C. Differences on RNA PAMPs direct co-stimulation in mouse and 
human CD4+ T-cells  
PRRs, in particular TLRs, are differentially expressed in mouse and 
human CD4+ T-cells (71). Recognition is also species-specific (48). To 
investigate whether there are differences in the direct responsiveness of human 
and mouse CD4+ T-cells to RNA-like IRMs (R-848 and poly I:C), CD4+ T-cells 
were isolated from human PBMCs. Similar to mouse CD4+ T-cells, human CD4+ 
T-cells were initially cultured at different anti-CD3 concentrations. In contrast to 
anti-CD3 stimulated mouse CD4+ T-cells, we detected IFN-γ production by 
human CD4+ T-cells in response to R-848 at anti-CD3 stimulation concentrations 
as low as 2 µg/ml (Figure 3.4). At 6 µg/ml, higher IFN-γ production was observed 
on R-848 stimulated human CD4+ T-cells compared to poly I:C stimulated 
human CD4+ T-cells (Figure 3.4). On the other hand, comparable Th1 and Th2 
effector cytokines levels were detected in R-848 and poly I:C stimulated human 
CD4+ T-cells, though predominantly slightly higher for poly I:C at 8 µg/ml anti-
CD3 concentration (Figure 3.5). 
 The imidazoquinoline-like molecule R-848 also activates TLR8 signaling in 
addition to TLR7 (48). Previous studies on TLR8 signaling suggested TLR8 to be 
non-functional in mice (70) but it was later demonstrated to be functional with the 
addition of poly (dT) in combination with TLR8 IRM in transfected HEK293 cells 
with murine TLR8 and in primary mouse cells (37). To investigate whether TLR8 
activation would explain the observed differences between mouse and human 
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Figure 3.4. R-848 and poly I:C have comparable direct co-stimulatory effects in 
anti-CD3 stimulated human CD4+ T-cells. FACS-sorted human CD4+ T-cells were 
cultured  for 3 days in anti-CD3 coated plates in the presence of R-848 or poly I:C. 
Anti-CD28 was also added as positive control. IFN-γ production of anti-CD3 stimulated 
(0 to 8µg/ml) CD4+ T-cells in the presence of R-848 and poly I:C. One representative 
experiment of three independent experiments is shown. 
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Figure 3.5. Luminex analysis of effector cytokines in anti-CD3 stimulated human 
CD4+ T-cells. Cell culture supernatants were collected at day 3 post stimulation of 
human CD4+ T-cells with anti-CD3 (8 µg/ml) + R-848 (20 µM), poly I:C (100 µg/ml) or 
anti CD28 (1.5 µg/ml). Supernatants were analyzed by Luminex® system for multiple 
cytokines. Replicates were pooled into one sample for analysis.  
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CD4+ T-cell responses to R-848 and poly I:C, we performed two preliminary 
TLR8 stimulation experiments. These experiments were done only once and we 
did not pursue these experiments. First, mouse CD4+ T-cells were cultured with 
the combination of R-848 and poly (dT) (3µM and 6µM) based on previous 
literature that functional murine TLR8 response needs poly (dT) enhancement 
(37). A slight, not statistically significant increase in IFN-γ production was 
observed in R-848/poly (dT)-stimulated mouse CD4+ T-cells (Figure 3.6a). We 
also explored the direct co-stimulation of TLR8 in human CD4+ T-cells in which 
we utilized CL075, a thiazoloquinolone derivative that stimulates TLR8 in human 
PBMCs (36). IFN-γ was produced by anti-CD3 stimulated human CD4+ T-cells 
with the addition of 50 ng/ml and 100 ng/ml of CL075 (Figure 3.6b). However, 
IFN-γ production was also observed in unstimulated human CD4+ T-cells (media 
only). These two preliminary experiments did not directly show R-848-mediated 
TLR8 signaling as the difference between mouse and human CD4+ T-cells. More 
definitive experiments such as TLR8 signaling blockade in human CD4+ T-cells 
and the use of TLR8-deficient mice would address and investigate TLR8 direct 
co-stimulation on CD4+ T-cells.  
 
D. Delineating poly I:C signaling in mouse CD4+ T-cells 
With the robust response that we observed in poly I:C direct co-stimulation 
of CD4+ T-cells, we focused on poly I:C signaling on CD4+ T-cells. MyD88-
independent poly I:C signals though TLR3/TRIF and the MDA5/IPS-1 signaling 
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Figure 3.6. Direct co-stimulatory activity by stimulation of TLR8 in mouse and 
human CD4+ T-cells. FACS-sorted mouse and human CD4+ T-cells were cultured  
for 3 days in anti-CD3 coated plates (8µg/ml) in the presence of R-848, poly I:C, 
poly(dT) (previously shown to activate murine TLR8 in combination with TLR8 IRMs) 
and CL075 (TLR8/7 IRM that stimulates TLR8 in human PBMCs). Anti-CD28 was 
added as positive control.  (A)  Mouse  CD4+ T-cells  (B) human CD4+ T-cells. Bars 
represent mean ± SEM (n=1). 
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pathways (106, 168).  Poly I:C also activates the NOD-like receptor (NLR) 
NLRP3 that oligomerizes upon activation and recruits ASC and procaspase-1 to 
form an inflammasome complex that activates caspase 1 (69). To delineate the 
RNA-sensing PRR pathways activated by poly I:C in anti-CD3 stimulated CD4+ 
T-cells, we utilized mice deficient in TLR3, TRIF, IPS-1, MDA-5, NLRP3, ASC, 
TRIF/MDA-5 and MyD88. Some of the knockout mice used were not fully 
backcrossed to the B6 background. F1 and F2 mice of C57BL/6J x 129S1/SvlmJ 
mice were used as wild type controls. 
Unexpectedly, poly I:C-induced IFN-γ production by mouse CD4+ T-cells 
was not abrogated in TLR3 deficient mice though a partial decrease was 
observed in IPS-1 deficient mice in one out of two experiments performed (Figure 
3.7a). Statistical analysis showed no significant differences between the TLR3 
and IPS-1 deficient mice.  TRIF-/-, MDA5-/- and TRIF-/-/MDA5-/- double-deficient 
CD4+ T-cells also gave similar results (Figure 3.7b&c). Poly I:C-induced IFN-γ 
production by mouse CD4+ T-cells was also not abrogated in NLRP3-/- and ASC-
/- mice (Figure 3.7d). On the other hand, poly I:C signaling in CD4+ T-cells was 
not affected in MyD88-/- CD4+T-cells, as expected (Figure 3.7d). Taken together, 
our data suggest that poly I:C signals through MyD88-independent signaling 
pathways other than TLR3/TRIF and RLR pathways.  
 The RNA-activated protein kinase (PKR) also recognizes poly I:C (109). 
To investigate PKR involvement in poly I:C signaling in CD4+ T-cells, mouse 
CD4+ T-cells were cultured in the presence of PKR inhibitors, 2-aminopurine and 
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Figure 3.7. Signaling pathways induced following poly I:C treatment. FACS-
sorted mouse CD4+ T-cells  from mice deficient in specific pattern recognition 
receptors and signaling mediators were stimulated with anti-CD3 (6µg/ml) to delineate 
poly I:C signaling in CD4+ T cells. FACS-sorted mouse CD4+ T-cells were cultured  for 
3 days in the presence of R-848, poly I:C and anti-CD28. Cell culture supernatants 
were measured for the presence of IFN-γ by ELISA. Some of the knockout mice used 
were not yet fully backcrossed to B6 background. F1 and F2 (C57BL/6J x 
129S1/SvlmJ) were used as wild type controls. (A) Anti-CD3 stimulation of F1, TLR3-/- 
and IPS-1-/- CD4+ T-cells (n=2, differences not significant)… 
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Figure 3.7. Signaling pathways induced following poly I:C treatment. (continued)  
…(B) F1, TRIF-/- and MDA5-/-  (n=1); (C) B6 and TRIF-/-/MDA5-/- (n=1) double knockout 
and… 
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RNA-dependent protein kinase inhibitor. The presence of these inhibitors 
abrogated IFN-γ production induced by poly I:C in mouse CD4+ T-cells. 
However, the inhibitors also abrogated the anti-CD28 positive control stimulation. 
The PKR inhibitors may be general serine/threonine kinase inhibitors or that 
these inhibitors induced cell death.  More definitive experiments must be 
performed such as the use of PKR-deficient mice to firmly establish PKR 
involvement in poly I:C induced IFN-γ production by mouse CD4+ T-cells and 
viability assays such as MTT or LDH assays to address cell death.   
 
E. Chapter Discussion  
Sensing of RNA PAMPs by RNA-sensing PRRs is essential to recognize 
RNA viruses. In this chapter, we focused on the RNA-sensing PRRs expressed 
in CD4+ T-cells and their role in modulating CD4+ responses. 
We focused on isolating ultrapure CD4+ T-cells to eliminate the secretion 
of cytokines by other cell types. In initial experiments, we utilized magnetically 
enriched (MACS) CD4+ T-cells and observed high IFN-γ production by R-848 
stimulated CD4+ T-cells. However, minimal IFN-γ production was observed with 
R-848 when CD4+ T-cells were sorted by FACS (>99.5% purity). The difference 
observed between MACS-enriched and FACS-sorted T-cells suggests that IFN-γ 
may have been produced by other non-CD4+ T-cells such as NK cells and γδ T-
cells. Poly I:C was previously shown to have direct co-stimulatory effect on 
human γδ T cells (170). Hence, CD4+ T-cells of high purity are required in the 
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anti-CD3 stimulation experiments to ensure that the IFN-γ measured is produced 
by CD4+ T-cells.   
RNA-like IRMs were previously shown to exert extrinsic activity on T-cells 
by activating and maturing APCs (2, 4, 94). Induction of cytokine production and 
proliferation in ultrapure CD4+ T-cells in our hands (where APCs were 
eliminated) suggest that there are differential intrinsic effects of RNA PAMPs and 
RNA-sensing PRR recognition in CD4+ T-cells. The minimal responses observed 
in the R-848-stimulated CD4+ T cell only (APC-free) system suggests the 
importance of R-848 signaling and RNA-sensing PRR recognition in APCs and 
non-CD4+ T-cells. On the other hand, the direct poly I:C signaling and RNA-PRR 
recognition in CD4+ T-cells may be sufficient to drive, not only Th1, but Th2 
responses. 
The observed higher R-848 induced Th1 responses in human CD4+ T-
cells compared to R-848 stimulated mouse CD4+ T-cells suggest that R-848 
activates TLR8 in human CD4+ T-cells. Although TLR7 and TLR8 are close 
phylogenetic relatives, mouse TLR8 was previously thought to be nonfunctional 
(37). The activation of murine TLR8 by RNA-like IRM requires poly (dT). The 
combination of R-848 and poly(dT) in anti-CD3 stimulation experiments slightly 
enhanced the IFN-γ production by mouse CD4+ T-cells. The observed increase 
suggests TLR8 signaling or the enhancement of TLR8 signaling by poly (dT), 
however, an increase in IFN-γ production in the presence of poly(dT) alone was 
also observed. This experiment was only done once and therefore more 
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definitive experiments should be performed. The use of other IRMs such as 3M-
001 (TLR7-selective) and 3M-002 (TLR8-selective) in anti-CD3 stimulated mouse 
CD4+ T-cells will allow us to delineate the contributions of each of these TLRs. 
These IRMs were used to demonstrate TLR8 to be functional in primary mouse 
PBMCs (37). The use of TLR8-deficient mice would provide more definitive 
results in the direct TLR8 co-stimulation of R-848 in CD4+ T-cells.  
Though we observed minimal direct co-stimulation effect with R-848, the 
multiple cytokine analyses with Luminex® showed the increase of Th1 and Th2 
cytokine production with both poly I:C and R-848. The up regulation of Th1 
responses for direct lysis and Th2 responses for stimulating antibodies are 
desirable for viral vaccines. With our results we showed MyD88-dependent (R-
848) and MyD88-independent (poly I:C) pathways can be directly stimulated in 
CD4+ T-cells to induce Th1 or Th2 responses. These results show the potential 
of R-848 or poly I:C as adjuvants in vaccines.     
The robust response that we observed in poly I:C stimulated CD4+ T-cells 
made it a more likely candidate than R-848 for delineating the RNA-sensing 
PRRs pathways activated intrinsically in CD4+ T-cells. Since poly I:C is 
recognized by TLR3, MDA5 and NLRP3, we utilized mice deficient in these RNA-
sensing PRRs and their signaling mediators. Interestingly, IFN-γ production by 
CD4+ T-cells was not abrogated in these gene-deficient CD4+ T-cells. These 
results led us to explore the involvement of PKR. Work from as early as the 
1980’s indicates that PKR is activated by cytoplasmic dsRNA. In some reviews, 
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PKR is described as a PRR for dsRNA (66, 113).  Researchers demonstrated 
that PKR was required for IFN production in bone marrow-derived DCs (25) and 
mouse embryonic fibroblasts (35) following poly I:C stimulation. PKR has also 
been shown to contribute to West Nile virus like particle-induced interferon 
production and could serve as a PRR for recognition of WNV infection (35). 
We observed complete abrogation of IFN-γ production by CD4+ T-cells 
with the use of PKR inhibitors, however, more definitive experiments should be 
performed, such as the use of PKR-deficient mice or the knockdown of PKR in 
CD4+ T-cells, to further address PKR involvement on the poly I:C direct co-
stimulation of CD4+ T-cells. 
We observed distinguishable differences between R-848 and poly I:C 
mediated co-stimulation of CD4+ T-cells but to fully discern the differences, more 
experiments should be performed. These include: the activation of transcription 
factors (IRFs, NF-κB, MAPKs), stimulation at different time points, determining 
cell death and viability after stimulation and to look at the cytotoxic activity of the 
RNA-like IRM treated CD4+ T-cells (by determining production of proteases 
involved in cell killing such as granzyme B). To further delineate poly I:C co-
stimulation signaling, treatment with Con A (an inhibitor of the V-type ATPase 
would abolish acidification of endosomes and thereby, poly I:C binding to TLR3) 
and Lyo-Vec-complexed poly I:C (which is recognized by MDA5 but not by TLR3) 
can be used to differentiate between TLR3 and MDA5 signaling in CD4+ T-cells 
(112).  
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F. Chapter Summary  
This chapter focused on the RNA-sensing PRRs expressed in mouse and 
human CD4+ T-cells. In these series of experiments, we have shown RNA-like 
IRMs to directly act on mouse and human CD4+ T-cells and enhance IFN-γ 
production. With the use of ultrapure CD4+ T-cells (without the confounding 
effects of non-CD4+ T-cell cytokine-producing lymphocytes) and mice deficient in 
specific PRRs and signaling mediators, we show variability in the responses 
elicited by RNA PAMPs and the direct co-stimulatory effects of RNA-like IRMs in 
mouse and human CD4+ T-cells. The results presented in this chapter suggest 
that recognition of RNA PAMPs and activation of the PRR pathways directly on 
CD4+ T-cells (intrinsic effect) induced cytokine production and proliferation in 
CD4+ T-cells.  
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CHAPTER IV 
CRITICAL RNA-SENSING PRR PATHWAYS ARE ACTIVATED BY RNA 
PAMPS/ADJUVANTS THAT DRIVE Th1 CD4+ T-CELL RESPONSES  
IN cDC/CD4+ T-CELL INTERACTIONS 
 
A. Introduction 
In this chapter, we set out to delineate the essential signaling pathways by 
which the RNA-like IRMs, R-848 and poly I:C, augment CD4+ Th1 responses. 
Highly purified conventional dendritic cells (cDCs) and conventional CD4+ T-cells 
were co-cultured in mixed leukocyte reactions (MLRs) in order to evaluate 
specific RNA-like adjuvant effects on these central mediators of primary immune 
responses. We found that R-848 was a more effective CD4+ Th1 adjuvant than 
poly I:C in isolated cDC/CD4+ T-cell interactions. Type I IFN production and Type 
I IFN receptor signaling in cDCs were necessary but not sufficient for the CD4+ 
T-cell adjuvant activity of R-848. Early and rapid IL-1α production and IL-1β 
secretion from cDCs were also necessary for CD4+ Th1 adjuvant properties of 
R-848.  Moreover, addition and blocking of these essential cytokines affect RNA-
like IRM stimulated CD4+ Th1 responses. Our results provide important insights 
into the key signaling pathways responsible for RNA-like IRM CD4+ T-cell 
activation, and will help in the rational design of improved vaccine adjuvants.  
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B. R-848>poly I:C augmented alloreactive CD4+ Th1 responses in a 
cDC/CD4+ T-cell MLR 
We utilized a MHC congenic MLR to investigate the essential signaling 
pathways by which RNA-like IRMs stimulate CD4+ Th1 responses.  Highly 
purified murine cDCs and highly purified MHC congenic conventional CD4+ 
T-cells were co-cultured for six days in the presence or absence of RNA-like 
IRMs. The cDCs and CD4+ T-cells were sorted by flow cytometry to high purity in 
order to eliminate the potential effects of bystander cells (e.g. natural killer cells, 
γδ T-cells).  Alloreactive CD4+ T-cell cytokine production was measured in cell 
culture supernatants and by ICS. At maximal doses, the murine TLR7 agonist R-
848 was a strong stimulator of alloreactive IFN-γ-producing CD4+ T-cells, 
whereas, the TLR3 and MDA5 agonist poly I:C was less potent in this system 
(Figures 4.1a&b). Nearly all R-848 or poly I:C stimulated IFN-γ+ CD4+ T-cells  
also produced TNF-α (Figure 4.1b). We used IFN-γ expression and production as 
a measure of RNA-like IRM augmentation of CD4+ Th1 responses. Our data 
indicate that RNA-like IRM activation of MyD88-dependent signaling pathways 
(R-848) stimulated CD4+ Th1 responses better than MyD88-independent 
signaling pathways (poly I:C) in isolated cDC/CD4+ T-cell interactions.   
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Figure 4.1. R-848 > poly I:C induces IFN-γ+ and TNF-α+ alloreactive CD4+ T-cells 
in a congenic MLR. Highly purified bone marrow-derived conventional dendritic cells 
(cDCs)(CD11c+CD11b+CD45R-/lo) and conventional CD4+ T-cells (CD3+ CD4+CD8-
TCRb+DX5-) were co-cultured for 6 d in the presence or absence of RNA-like IRMs.  (A) 
Cell culture supernatant IFN-γ levels measured by ELISA. Values are mean ± SEM 
(n=3), **R-848 p<0.0001 compared to media control; *poly I:C p=0.0343 compared to 
media control (representative of at least three independent experiments shown).  (B) 
ICS staining for IFN-γ and TNF-α producing conventional CD4+ T-cells. Values  shown 
are the % of CD3+CD4+ T-cells producing IFN-γ (left column) and % IFN-γ+TNF-α-, IFN-
γ-TNF-α+, or IFN-γ+TNF-α+ (right column) (representative of three independent 
experiments shown, left column and right column were from different experiments). 
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C. Type I IFN signaling in cDCs was necessary to stimulate CD4+ Th1 
responses in a cDC/CD4+ T-cell MLR 
RNA-like IRMs and RNA-sensing PRRs induce Type I IFN production and 
signaling in cDCs (98, 130). Type I IFN can drive DC maturation and activation 
(140). IFN-γ responses were abolished when cDCs from IFNAR-/- mice were used 
in MLRs compared to cDCs from wild-type B6 mice (Figures 4.2 a&b). The small 
increase in alloreactive CD4+ T-cell IFN-γ responses induced by poly I:C was 
also abrogated when cDCs from IFNAR-/- mice were used. Type I IFN signaling in 
cDCs was essential for the ability of R-848 and poly I:C to augment alloreactive 
CD4+ T-cell IFN-γ production in isolated cDC/CD4+ T-cell interactions. However, 
R-848 induced much lower IFN-β mRNA levels in cDCs compared to poly I:C 
(Figure 4.2c), and yet stimulated much higher CD4+ T-cell IFN-γ responses 
compared to poly I:C. This suggested that Type I IFN production and signaling in 
cDCs was essential but not sufficient for optimal RNA-like IRM stimulation of 
CD4+ Th1 responses.    
 
D. R-848 stimulation of CD4+ Th1 responses was dependent on MyD88-
mediated signaling in cDC and conventional CD4+ T-cells 
R-848 activates murine TLR7/MyD88-dependent signaling (49). R-848 has 
been reported to have direct effects on cDCs and CD4+ T-cells (17, 71, 134). We 
therefore examined the role of MyD88-dependent signaling pathways in cDCs 
and CD4+ T-cells during R-848 stimulation of alloreactive CD4+ Th1 responses. 
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Figure 4.2. Type I IFN is essential for RNA-like IRMs to stimulate CD4+ Th1 
responses in a cDC/CD4+ T-cell MLR.  (A) IFN-γ levels in cell culture supernatants 
measured by ELISA in MHC congenic MLRs utilizing B6 or IFNAR-/- cDCs and B6.H2d 
CD4+ T-cells. Values are mean ± SEM (n=3). ** p=0.0008 compared to R-848 
stimulated B6 cDC MLR, * p=0.0037 compared to poly I:C stimulated B6 cDC MLR.  (B) 
ICS staining for IFN-γ producing conventional CD3+CD4+ T-cells in MHC congenic 
MLRs utilizing B6 or IFNAR-/- cDCs and B6.H2d CD4+ T-cells (representative of three 
independent experiments shown). Values shown are the % of IFN-γ+ conventional 
CD3+CD4+ T-cells.  (C) cDCs were stimulated with R-848, poly I:C, or media 
(unstimulated control), and cellular RNA was collected at the indicated time points. IFN-
β mRNA levels were measured by qRT-PCR, as described in the Methods section. Bars 
represent fold-change in IFN-β mRNA relative to unstimulated control at the 6 h time 
point (mean ± SEM, n=3).  
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Not surprisingly, IFN-γ production was entirely abrogated when MyD88-/- or 
TLR7-/- cDCs and B6.H2d CD4+ T-cells were used in MHC congenic MLRs 
(Figure 4.3a). IFN-γ production was also decreased when B6.H2d cDCs and 
MyD88-/- conventional CD4+ T-cells were used in MLRs (Figure 4.3b). This 
MyD88-dependence in conventional CD4+ T-cells was not mediated through 
TLR7 or IL-18 receptor signaling (Figure 4.3b and Figure 4.4 a&b). The data 
indicate that R-848 activation of TLR7/MyD88-dependent signaling in cDCs was 
critical for augmenting alloreactive CD4+ Th1 responses, and that TLR7-
independent/MyD88-dependent signaling in CD4+ T-cells was also essential.  
 
E. cDC IL-1α and IL-1β production and IL-1R-mediated signaling in 
cDCs and conventional CD4+ T-cells, were essential for R-848 stimulation 
of CD4+ Th1 responses 
We next explored the role of IL-1R/MyD88 signaling in R-848 stimulation of 
CD4+ Th1 responses. When IL-1R-/- cDCs and B6.H2d CD4+ T-cells were used 
in the MHC congenic MLRs, IFN-γ production was 45 ± 9% lower compared to 
responses when wild-type cDCs were used (mean±SEM, n=3, p=0.03) (Figures 
4.5 a&b). Similarly, when B6.H2d cDCs and IL-1R-/- CD4+ T-cells were used in 
MHC congenic MLRs, IFN-γ production was 55 ± 5% lower compared to 
responses when wild-type CD4+ T-cells were used (mean±SEM, n=3, 
p=0.01)(Figures 4.5 c&d). The observed effect of eliminating IL-1R-mediated 
signaling on R-848 stimulation of CD4+ Th1 responses in both cDC and CD4+ T-
63
A 
 
media R-848 
B6  
MyD88-/-  
IFN-γ 
CD4 
TLR7-/-  
cDC 
media R-848 
CD4 
CD4+ T-cell 
IFN-γ 
B 
Figure 4.3. TLR7 signaling in cDCs, and TLR7-independent/MyD88-mediated 
signaling in CD4+ T-cells, are essential for R-848 induced CD4+ Th1 responses. 
(A) ICS staining for  IFN-γ producing CD4+ T-cells in MHC congenic MLRs utilizing B6, 
MyD88-/-, or TLR7-/- cDCs and B6.H2d CD4+ T-cells (representative of two independent 
experiment shown) (B) ICS staining for  IFN-γ producing CD4+ T-cells in MHC congenic 
MLRs utilizing  B6.H2d cDCs and B6, MyD88-/-, or TLR7-/- CD4+ T-cells (representative 
of two independent experiments shown). Values shown are the frequencies of IFN-γ+ 
conventional CD3+CD4+ T-cells. 
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Figure 4.4. MyD88-dependence in conventional CD4+ T-cells was not mediated 
through IL-18 receptor signaling. (A) Cell culture supernatant IFN-γ levels (day 6) in 
MHC congenic MLRs utilizing B6.H2d cDCs and B6 or IL-18R-/- CD4+ T-cells. Values 
are mean ± SEM. (B) ICS staining for IFN-γ producing CD4+ T-cells in MHC congenic 
MLRs utilizing B6.H2d cDCs and B6 or IL-18R-/- CD4+ T-cells. Values shown are the 
frequencies of IFN-γ+ CD3+CD4+ T-cells (n=3). 
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Figure 4.5. IL-1R-mediated signaling in cDCs and conventional CD4+ T-cells are 
essential for R-848 stimulation of CD4+ Th1 responses. (A) IFN-γ levels in cell 
culture supernatants in MHC congenic MLRs utilizing B6 or IL-1R-/- cDCs and B6.H2d 
CD4+ T-cells. Values are mean ± SEM (n=3). (B) ICS staining for IFN-γ producing 
conventional CD3+CD4+ T-cells in MHC congenic MLRs utilizing B6 or IL-1R-/- cDCs 
(allogeneic MLR, representative of two experiments, n=3). Values shown are the % of 
IFN-γ+ conventional CD3+CD4+ T-cells…   
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Figure 4.5. IL-1R-mediated signaling in cDCs and conventional CD4+ T-cells are 
essential for R-848 stimulation of CD4+ Th1 responses. (continued)… (C) IFN-γ 
levels in cell culture supernatants in MHC congenic MLRs utilizing B6.H2d cDCs and B6 
or IL-1R-/- CD4+ T-cells. Values are mean ± SEM (n=3). (D) ICS staining for IFN-γ 
producing conventional CD3+CD4+ T-cells in MHC congenic MLRs utilizing B6.H2d cDCs 
and B6 or IL-1R-/- CD4+ T-cells (congenic MLR, only one experiment done, n=3). Values 
shown are the % of IFN-γ+ conventional CD3+CD4+ T-cells. 
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cells prompted us to examine IL-1α and IL-1β production by cDCs.  
R-848-induced alloreactive CD4+ T-cell IFN-γ production was decreased when 
IL-1α-/-, IL-1β-/-, or IL-1αβ-/- cDCs and B6.H2d CD4+ T-cells were used in the 
MLRs (Figures 4.6 a&b).  IL-1α and IL-1β had largely non-redundant roles in 
driving the alloreactive CD4+ Th1 responses to R-848 in this system. 
Collectively, our data suggest that the Type I IFN, IL-1α, and IL-1β are all 
necessary for the optimal stimulation of CD4+ Th1 responses by RNA-like IRMs. 
 
F. R-848 rapidly increases cDC production of pro-IL-1α and pro-IL-1β 
mRNA and protein 
We next explored the differences in the kinetics of IL-1α and IL-1β 
production by R-848- and poly I:C-stimulated cDCs. R-848 stimulation of cDCs 
produced a rapid upregulation of pro-IL-1α and pro-IL-1β mRNA (Figures 4.7 
a&b), whereas, poly I:C stimulation of cDCs produced a slower and more gradual 
increase in pro-IL-1α and pro-IL-1β mRNA expression (Figures 4.7 c&d). 
Biologically active IL-1α (precursor and mature IL-1α) is primarily intracellular 
and membrane-associated, while biologically active IL-1β (mature IL-1β) is 
primarily secreted (27). Comparable levels of IL-1α protein (precursor and 
mature forms) were measured in the cell lysates from R-848 and poly I:C-
stimulated cDCs at early time points (Figure 4.8). R-848 and extracellular ATP 
stimulation of cDCs rapidly induced higher levels of secreted mature IL-1β 
68
A 
Figure 4.6. IL- 1α and IL-1β are essential for R-848 stimulation of CD4+ Th1 
responses. (A) IFN-γ levels in cell culture supernatants (day 6) in MHC congenic 
MLRs utilizing B6, IL-1α-/- , IL-1β-/- or IL-1α-/-β-/- cDCs and B6.H2d CD4+ T-cells. 
Values are mean ± SEM (n=6). *p<0.05 compared to R-848 stimulated B6 cDC 
MLR.  (B) ICS staining for IFN-γ producing CD4+ T-cells in MHC congenic MLRs 
utilizing B6, IL-1α-/- , IL-1β-/- or IL-1 α-/-β-/- cDCs and B6.H2d CD4+ T-cells 
(representative of two independent experiments shown). Values shown are the % 
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Figure 4.7. R-848 induces a rapid increase in pro-IL- 1α and pro-IL-1β mRNA 
expression and protein production in cDCs. cDCs were stimulated with R-848, 
poly I:C, or media (unstimulated control), and cellular RNA and cell culture 
supernatants were collected at the indicated time points. Pro-IL- 1α (A&B) and 
pro-IL-1β (C&D) mRNA levels were measured by qRT-PCR, as described in the 
Methods section. Bars represent fold-change in pro-IL- 1α or pro-IL-1β mRNA 
relative to unstimulated control at the 6 h time point (mean ± SEM, n=3). (E&F) IL-
1β protein levels (precursor and mature forms) were measured in cell culture 
supernatants by ELISA (mean ± SEM, n=3).  
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Figure 4.8. Comparable levels of IL-1α protein (precursor and mature forms) were 
measured in R-848 and poly I:C-stimulated cDCs. cDCs were stimulated with R-848, 
poly I:C, or media (unstimulated control), and the cell lysates were collected at the 
indicated time points. Pro-IL- 1α protein levels were measured by ELISA (representative 
of one out of two independent experiments shown). 
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protein in cell-free culture supernatants compared to poly I:C and extracellular 
ATP (Figures 4.7 e&f and Figure 4.9).  
To further show the essential roles of type I IFN, IL-1α and IL-1β in driving 
CD4+ Th1 responses, we added recombinant type I IFN, IL-1α and IL-1β to the 
MLR to determine whether these cytokines could increase IFN-γ levels in CD4+ 
T-cells. We found that type I IFN (200 U/ml), rIL-1α (125 pg/ml) and rIL-1β (125 
pg/ml) were sufficient to induce a three-fold increase in IFN-γ production. IFN-γ 
levels following treatment with recombinant cytokines were comparable to 
responses when poly I:C was used in MLR (Figure 4.10).  
In MHC congenic MLRs, poly I:C treatment induced rapid and sustained 
Type I IFN production (Figure 4.2c). Pro-IL-1α and pro-IL-1β were induced by 
poly I:C at later time points compared to R-848 (Figure 4.7). To further examine 
the early roles of IL-1α and IL-1β, we added mouse rIL-1α and rIL-1β at the same 
time as poly I:C in MHC congenic MLRs. Addition of rIL-1α and rIL-1β increased 
poly I:C induced cytokine-producing (IFN-γ, TNF-α and IL-2) CD4+ T-cells 
(Figure 4.11). The data indicate that early IL-1α and IL-1β production and 
signaling are essential for the robust RNA-like IRM stimulation of CD4+ Th1 
responses. 
 
G. Inhibition of IL-1 and Type I IFN signaling abrogated R-848 
stimulation of CD4+ Th1 responses 
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Fig. 4.9. R-848 and extracellular ATP stimulates early mature IL-1β secretion 
from cDCs.  Non-primed DCs were stimulated for 6 h with R-848 or poly I:C with 
extracellular ATP (5 mM). As a positive control, cDCs were primed with 
lipopolysaccharide (200 ng/ml) for 3 hours prior to stimulation with nigericin (10 
µM). Mature IL-1β protein was detected by Western blot in cell culture 
supernatants. Data shown is representative of three independent experiments. 
media (+) Ctrl R-848 Poly I:C 
pro IL-1β 
mature   
IL-1β 
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Figure 4.10. Addition of type I IFN, rIL-1α and rIL-1β  increased IFN-γ production in 
CD4+ T-cells. IFN-γ levels (day 6) in cell culture supernatants in MHC congenic MLRs. 
200 U/ml type I IFN and 125 pg/ml of rIL-1α and rIL-1β were added to MHC congenic 
cDC/CD4+ MLRs. Values shown are mean IFN-γ levels (ng/ml) ± SEM (n=2).  
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Figure 4.11.  The addition of rIL- 1α and rIL-1β increased poly I:C-induced 
CD4+ Th1 responses in a cDC/CD4+ T-cell MLR. (A) IFN-γ levels in cell culture 
supernatants in poly I:C stimulated MHC congenic MLR with mouse rIL- 1α and 
rIL-1β. ICS staining for IFN-γ (B), TNF-α (C) and IL-2 (D) producing conventional 
CD4+ T-cells. Values are mean ± SEM (n=3) (representative of two independent 
experiments shown). *p<0.05 compared to media control.  
B 
C D 
     
IF
N
- γ
 (
ng
/m
l)
media poly I:C IL-1 poIy I:C + IL-1
0
20
40
60
*
    
%
 IF
N
- γ
+ 
C
D
4 
T-
ce
lls
media poly I:C IL-1 poly I:C + IL-1
0
1
2
3
    
%
 T
N
F+
 C
D
4 
T
-c
el
ls
media poly I:C IL-1 poly I:C + IL-1
0
1
2
3
4
*
    
%
 IL
-2
+ 
C
D
4 
T
-c
el
ls
media poly I:C IL-1 poly I:C + IL-1
0.0
0.5
1.0
1.5 *
75
To further assess the role of IL-1 in R-848-induced CD4+ Th1 responses, a 
natural inhibitor of IL-1 signaling, sIL-1Ra, and its synthetic form, AnakinraTM, 
were added to R-848 stimulated MHC congenic MLRs. To inhibit Type I IFN 
signaling, antibodies against the IFN α/β receptor were also added. Inhibition of 
both IL-1 and Type I IFN signaling diminished the robust R-848 induced CD4+ 
Th1 responses (Figure 4.12). Inhibition of either IL-1 or Type I IFN signaling also 
reduced R-848 induced CD4+ Th1 responses but to a lesser degree (Figure 
4.12).  Taken together, Type I IFN production and signaling by itself was not 
sufficient to drive RNA-like IRM stimulated CD4+ Th1 responses. The combined 
actions of Type I IFN, IL-1α, and IL-1β were essential for the optimal activation of 
alloreactive CD4+ Th1 responses in cDC/conventional CD4+ T-cell interactions.  
 
H. Chapter Discussion 
There is a growing need for novel vaccine adjuvants with potent T-cell 
immune stimulatory effects. In this chapter, we investigated the critical cellular 
signaling pathways used by RNA-like IRMs (R-848 and poly I:C) to stimulate 
CD4+ Th1 responses during alloreactive cDC/CD4+ T-cell interactions. RNA-like 
IRM stimulation of Type I IFN production and signaling was essential but not 
sufficient for driving CD4+ Th1 responses. The rapid and early production of 
IL-1α and IL-1β was equally critical for the optimal activation of Th1 CD4+ 
T-cells. In cDCs, R-848 activation of TLR7/MyD88-dependent signaling led to a 
rapid upregulation of pro-IL-1α and pro-IL-1β production compared to poly I:C 
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Figure 4.12. Inhibition of Type I IFN, IL- 1α and IL-1β signaling decreases R-848-
induced CD4+ Th1 responses. Type I IFN and IL-1 signaling was blocked with anti-
mouse IFN α/β receptor, AnakinraTM and sIL-1Ra. IFN-γ levels (day 6) in cell culture 
supernatants were measured in MHC congenic MLRs with treated and mock treated 
cells. Blocking of either Type I IFN or IL-1α/β signaling decreased IFN-γ levels in cell 
culture supernatants. Values are mean ± SEM (n=6). *p<0.05 compared to R-848 
stimulated MLR (black bar). 
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activation of MyD88-independent signaling pathways.  R-848 stimulated the early 
production and secretion of mature IL-1β from cDCs and augmented alloreactive 
CD4+ Th1 responses to a greater degree than poly I:C. Our data suggests that 
the CD4+ T-cell adjuvant activity of RNA-like IRMs is mediated by a critical 
combination of rapid Type I IFN, IL-1α and mature IL-1β production.  
The RNA-like IRMs, R-848 and poly I:C, are well-known inducers of Type I 
IFN in many cell types and have been shown to be potent CD4+ T-cell adjuvants 
(2, 130, 132, 165). Longhi et al. (98) primed and boosted mice with a dendritic 
cell targeted HIV gag protein vaccine and TLR agonists. They found poly I:C to 
be the most effective inducer of Type I IFN and the superior adjuvant to elicit 
CD4+ T cell immunity. Antibody blocking or deletion of Type I IFN receptor 
markedly reduced DC maturation, T-cell proliferation, and the development of 
adaptive Th1 immunity in response to the HIV gag protein.  Ichinohe et al. (60) 
also investigated the mucosal adjuvant effect of poly I:C by intranasal co-
administration with inactivated influenza virus HA vaccines and observed cross-
protection against heterologous infection. The authors observed upregulated 
expression of Type I IFN, and Th1/Th2 cytokines following the administration of 
HA vaccine with poly I:C. Vasilakos et al. (165) demonstrated that mice 
immunized with chicken ovalbumin and R-848 induced high levels of Type I IFN, 
and neutralizing antibodies to Type I IFN inhibited ovalbumin-specific CD4+ Th1 
responses. Similarly, in isolated cDC/CD4+ T-cell interactions, we found that 
Type I IFN production and signaling was necessary for the activation of Th1 
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alloreactive CD4+ T-cells by RNA-like IRMs. However, poly I:C was a more 
potent inducer of Type I IFN in highly purified cDCs compared to R-848, yet it 
was less potent at stimulating alloreactive CD4+ Th1 responses. This suggested 
that Type I IFN production and signaling in cDCs was essential but not sufficient 
for RNA-like IRMs to augment CD4+ Th1 responses in isolated alloreactive 
cDC/CD4+ T-cell interactions. 
We found that the ability of R-848 to augment alloreactive CD4+ Th1 
responses in a cDC/CD4+ T-cell MLR was also dependent on the early and rapid 
production of functional IL-1α and IL-1β from cDCs. MyD88-dependent IL-1R 
mediated signaling in both cDCs and CD4+ T-cells was important in mediating 
the CD4+ Th1 stimulatory effect of R-848.  IL-1 stimulates cDC maturation and 
activation (43, 101) and can act directly on CD4+ T-cells to enhance their 
differentiation and cytokine production (11). T-cells can also produce IL-1 and 
appears to serve an autocrine role in T-cell activation (156, 164). 
The Th1 adjuvant effects of IL-1 have been previously reported in in vivo 
studies. Ben-Sasson et al. (11), used recipient mice that were immunized with 
pigeon cytochrome C peptide together with different proinflammatory cytokines 
(administered through a miniosmotic pump). Only IL-1 augmented primary 
immune responses among a series of cytokines tested, including TNFα, IL-1, 
IL-6, IL-18 and IL-33. IL-1α and IL-1β displayed similar potency (11). The timing 
and the concentration of IL-1 are critical for an optimal effect. Staruch et al. (152) 
have shown that the optimal adjuvant effect of IL-1 was 2 hours after the priming 
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dose of bovine serum albumin (BSA) protein antigen. These authors have also 
observed dose-dependent enhancement of CD4+ T-cell responses to BSA. 
Similarly, in our MHC congenic MLR system, we found that the early addition of 
IL-1 was necessary for increased adjuvant effects of poly I:C. 
The observed comparable decreases in the frequencies of IFN-γ producing 
CD4+ T cells when utilizing IL-1α-/-, IL-1β-/- and IL-1αβ-/- cDCs in the MLRs 
suggested that IL-1α and IL-1β have largely non-redundant roles in stimulating 
alloreactive CD4+ Th1 responses. Though IL-1α and IL-1β both bind and activate 
IL-1R (26), differences in their localization might explain their apparent 
non-redundant effects (27, 29, 103). Biologically active IL-1α (precursor and 
mature forms) is predominantly cell- and membrane-associated (93), and likely 
acts in an autocrine or even intracrine manner in antigen-presenting cells (27). 
The pro-IL-1α is processed by calpain (7, 102) and heat shock, calcium 
ionophores and ATP have all been shown to stimulate the release of mature IL-
1α in vitro (102). In contrast, pro-IL-1β is biologically inactive and has different 
posttranslational processing requirements than pro-IL-1α. Caspase-1-containing 
inflammasomes (e.g. NLRP3 inflammasome) cleave pro-IL-1β into the 
biologically active mature form which is secreted into the extracellular 
environment in a non-classical manner (29, 104). Thus, mature IL-1β likely acts 
predominantly in a paracrine or endocrine manner, activating IL-1R signaling in 
effector cells such as CD4+ T-cells. The preferential cell association of IL-1α, in 
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contrast to the existence of IL-1β primarily as a soluble protein; difference in 
processing and release may all be important in explaining the non-redundant 
effects for these two types of IL-1.     
Other studies conducted on IL-1α and IL-1β-deficient mice have also shown 
non-redundant roles for these cytokines in immune responses and disease 
pathogenesis. IL-1β, but not IL-1α, was required for antigen-specific T-cell 
activation in delayed-type hypersensitivity responses (120) and in T-cell 
dependent antibody production against sheep red blood cells (55, 118). IL-1α, 
but not IL-1β, modulated the antiviral and immunoregulatory activities of IFN-γ 
(55), and was necessary for cell- and tissue-injury induced sterile inflammatory 
responses (18). Further studies are needed to discriminate the potential 
non-redundant roles of IL-1α and IL-1β in the RNA-like adjuvant augmentation of 
CD4+ Th1 responses. 
IL-1α is secreted to a much lesser extent than IL-1β. It is not commonly 
detected in body fluids except during severe inflammation in which, pro-IL-1α is 
possibly released from necrotizing cells (18, 102, 115). It is therefore possible 
that RNA-like IRMs trigger cell death that consequently releases IL-1. We 
performed some cell death assays (MTT assay, data not shown) but we did not 
see any significant differences. In our ICS analyses, we used LIVE/DEAD cell 
stain kit to exclude nonviable cells. No notable increase in dead lymphocytes was 
observed in the presence of RNA-like IRMs (data not shown). Hence, our 
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observations suggest that the concentrations of RNA-like IRMs that we used in 
MLRs did not cause cell death. 
In cDCs, R-848 induced less Type I IFN but early and more robust IL-1α and 
IL-1β production than poly I:C. R-848 was also a more potent CD4+ T-cell 
adjuvant compared to poly I:C in the cDC/CD4+ T-cell MHC congenic MLR 
system. However, poly I:C has also been shown to be a potent CD4+ T-cell 
adjuvant in vivo (60, 98, 163). When administered as an adjuvant in mice, the 
main source of poly I:C-induced Type I IFN has been reported to be non-
hematopoietic cells (98). In addition, poly I:C has been shown to induce mRNA 
expression (105) and protein production of IL-1 both in vitro (5, 131) and in vivo 
(5, 30, 133).  In our isolated cDC/CD4+ T-cell MHC congenic MLR, poly I:C 
stimulation did not induce sufficient Type I IFN and IL-1.  The increase in CD4+ 
Th1 responses with exogenous rIL-1 in poly I:C stimulated MHC congenic MLRs 
supports this hypothesis. Furthermore, increased Type I IFN production has been 
shown to inhibit IL-1 production (40). In the said paper, the investigators found 
that type I IFN strongly suppressed IL-1 production through two distinct 
mechanisms – STAT1 dependent inhibition of NLRP3 and NLRP1 inflammasome 
activity and the enhanced production of IL-10 of bone marrow-derive 
macrophages that decreased the levels of pro-1L-1α and pro-IL-1β. The delayed 
IL-1 production observed in poly I:C stimulated MHC congenic MLRs may be an 
effect of the robust poly I:C-induced type I IFN in the isolated cDC/CD4+ T-cell 
MLR system that consequently inhibited IL-1 production.  
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The essential roles of these cytokines were also evident in the abrogation of 
CD4+ Th1 responses upon Type I IFN and IL-1 signaling blockade in R-848 
stimulated MHC congenic MLRs.  The observed differences in the cDC 
production of type I IFN, IL-1α and IL-1β between R-848 and poly I:C in MHC 
congenic MLRs indicate that there are complex signaling cascades for the 
initiation of CD4+ Th1 responses. Complete elucidation and a better 
understanding of these mechanisms would offer further possibilities for the use of 
these RNA-like IRMs as adjuvants. 
We observed that the ability of R-848 to augment alloreactive CD4+ Th1 
responses was also dependent on MyD88-mediated signaling in the CD4+ T-
cells but not fully MyD88-dependent as observed in cDCs. This suggests that 
MyD88-dependent signaling is important in R-848 stimulated cDC cytokine 
production and is also intrinsically essential in CD4+ T-cells. IL-1R mediated 
signaling could only explain part of this profound CD4+ T-cell MyD88 signaling 
dependence. The isolated removal of CD4+ T-cell TLR7 or IL-18 receptor 
signaling did not affect R-848 induced alloreactive CD4+ Th1 responses. It is 
possible that there is overlap and a partial redundancy of the signaling effects in 
CD4+ T-cells among IL-1R, IL-18R, and TLR7/MyD88 dependent pathways. It is 
also be possible that other MyD88-dependent signaling pathways in CD4+ T-
cells, yet to be identified, are involved in priming and activation (177).  
In summary, RNA-like IRMs are effective CD4+ Th1 adjuvants and their ability 
to induce Type I IFN is critical for their T-cell stimulatory activity. In MLRs utilizing 
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two specific cell types, cDCs and conventional CD4+ T-cells, we have shown that 
early and rapid IL-1α and mature IL-1β production are equally critical with Type I 
IFN production. Upon RNA-like IRM stimulation, Type I IFN, IL-1α and IL-1β 
mainly produced by cDCs drive the activation of CD4+ Th1 responses. R-848-
mediated CD4+ Th1 responses are mainly TLR7/MyD88-dependent in cDCs. 
MyD88 signaling is also important in CD4+ T-cells but not mediated by TLR7 
signaling. Together, these results show that the CD4+ T-cell adjuvant activity of 
RNA-like IRMs involves a complex interplay of critical PRR and innate immune 
signaling pathways in different cells. 
 
I. Chapter Summary 
There is a growing need for novel vaccine adjuvants that can provide safe 
and potent T-helper type 1 (Th1) activity. RNA-like immune response modifiers 
(IRMs) are candidate T-cell adjuvants that skew acquired immune responses 
towards a Th1 phenotype. In this chapter, we set out to delineate the essential 
signaling pathways by which the RNA-like IRMs, resiquimod (R-848) and 
polyinosinic:polycytidylic acid (poly I:C), augment CD4+ T-helper 1 (Th1) 
responses. Highly purified murine conventional dendritic cells (cDCs) and 
conventional CD4+ T-cells were co-cultured in allogeneic and MHC congenic 
mixed leukocyte reactions.  The activation of CD4+ Th1 cells was examined 
utilizing cells from mice deficient in specific RNA-sensing pattern recognition 
receptors and signaling mediators. R-848 and poly I:C stimulation of Type I 
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interferon production and signaling in cDCs was essential but not sufficient for 
driving CD4+ Th1 responses. The early and rapid production of IL-1α and IL-1β 
was equally critical for the optimal activation of Th1 CD4+ T-cells. R-848 
activation of Toll-like receptor 7/MyD88-dependent signaling in cDCs led to a 
rapid upregulation of pro-IL-1α and pro-IL-1β production compared to poly I:C 
activation of MyD88-independent signaling pathways. The in vitro data show that 
CD4+ T-cell adjuvant activity of RNA-like IRMs is mediated by a critical 
combination of early and rapid Type I interferon, IL-1α and IL-1β production. 
These results provide important insights into the key signaling pathways 
responsible for RNA-like IRM CD4+ Th1 activation.  A better understanding of the 
critical signaling pathways by which RNA-like IRMs stimulate CD4+ Th1 
responses is relevant to the rational design of improved vaccine adjuvants. 
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CHAPTER V: 
CONTRIBUTIONS OF RNA-SENSING PRR PATHWAYS ON Th1 
RESPONSES TO INFLUENZA A VIRUS INFECTION 
 
A.  Introduction 
To explore further the contributions of RNA-sensing PRRs in the 
modulation of immune responses, we utilized an influenza A virus (IAV) mouse 
infection model and mice deficient in specific RNA-sensing PRRs and signaling 
mediators.  
 RNA-sensing PRRs, mediate the initial recognition of IAV and shape the 
adaptive immune response (69). This includes the MyD88 signaling dependent 
TLR7 (24) and the MyD88 signaling independent receptors TLR3 (42), RIG-I (81) 
and NLRP3 (78). MyD88 signaling has been found to be essential for the optimal 
protection against various pathogens including homologous challenge with IAV 
(145).  However, the role of MyD88 signaling in heterosubtypic IAV infections is 
not well characterized.  
In this chapter, we utilized a murine model of heterosubtypic IAV infections 
(9, 22) in which we examined the role of MyD88 signaling in heterosubtypic 
adaptive immune responses (T-cell and Ab responses) to the internal proteins of 
IAV.   
 
B.  Heterosubtypic immunity to influenza A viruses 
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Mice were infected intranasally with a sublethal dose of A/Puerto 
Rico/8/34 (PR/8) (H1N1). Mice were then challenged intranasally 21 days later 
with a sublethal dose of A/HK/X31 (HK/X31) (H3N2), a strain that contains all the 
internal proteins of PR/8 (6 out of 8 of the total genome) (88). We examined 
memory T-cell and Ab responses to influenza A PR/8 internal proteins 7 days 
after the second IAV infection (Figure 5.1).  This allowed us to examine 
heterosubtypic immune responses to IAVs without the confounding effects of 
anti-hemagglutinin protective Abs.     
 
C.  A MyD88-mediated signaling pathway is required for the induction of 
heterosubtypic CD4+ T-cell immune responses to IAV.   
In a murine homologous IAV challenge model, splenic CD4+ T-cell 
immune responses have been previously reported to be dependent on 
TLR7/MyD88 signaling (90).  We infected B6 mice with10 pfu PR/8 and later 
challenged these mice with 104 pfu HK/31. We found that anti-IAV NP311-325 
CD4+ T-cell IFN-γ and TNFα production in the lung and spleen were dependent 
on MyD88 signaling (Figures 5.2 & 5.3).  Some of these NP311-325 specific CD4+ 
T-cells produced both cytokines (Figure 5.4).  Anti-IAV NP311-325 CD4+ Th1 
cytokine production in the lung and spleen was MyD88 dependent, but the 
frequencies of CD3+CD4+ T-cells at these two sites were not (Figure 5.2c & 
5.3c).  We further found that lung anti-IAV NP311-325 CD4+ Th1 cytokine 
production was partially dependent (but not statistically significant) on TLR7 
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21 days 7 days 
Collect: 
1. Spleen CD4+ & CD8+ T-cells  
    (IFN-γ & TNFα ICS) 
2. Lung CD4+ & CD8+ T-cells  
    (IFN-γ & TNFα ICS) 
3. Serum IgG2c & total IgG 
    (PR8 NP protein-specific ELISA) 
-  H3 
-  H1 
Legend: 
-  N1 
-  N2 
Figure 5.1. Heterosubtypic immunity to influenza A virus (IAV) internal proteins. B6 
mice were infected intranasally (i.n.) with 10 plaque forming units (pfu) of PR/8 and 
challenged 21 days later with 10,000 pfu of HK/X31. 7 days after HK/X31 infection, 
spleen and lungs were collected for intracellular cytokine staining (ICS) and the serum 
was used to measure NP-specific IgG levels by ELISA. PR/8 and HK/X31 IAVs have 
different hemagglutinin (HA) and neuraminidase (NA) surface proteins and are not 
recognized by any cross-reactive neutralizing antibodies. These IAV strains share 6 
internal genes derived from PR/8 – NP, the polymerase complex heterotrimer (PB2, PB1 
and PA), matrix protein (M) and nonstructural protein (NS). 
PR8 HKx31 
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Figure 5.2. IFN-γ or TNFα production by IAV-specific CD4+ T-cells in the spleen. 
Splenocytes from mice infected with PR/8 and HK/X31 IAVs, as described in Figure  
5.1, were stimulated for 6 hrs with nucleoprotein (NP)311-325 peptide, a MHC Class II 
restricted PR/8 IAV epitope. NP311-325-specific cytokine-producing CD4+ T-cells were 
identified as CD3+CD4+CD8-IFN-γ+ (A) or TNFα+ T cells (B). NP311-325-specific 
cytokine-producing CD4+ T-cells were analyzed in B6, MyD88-/- and TLR7-/- mice. The 
frequencies of spleen CD3+CD4+ T-cells in these mouse strains were also 
determined (C). Values shown (A & B) are the % of IFN-γ+ or TNFα+ NP311-325-specific 
splenic CD4+ T-cells minus unstimulated background. Bars are median values. 
*p<0.05 compared to NP311-325-specific B6 splenic CD4+ T-cells. (B6 n=31; MyD88-/- 
n=12; TLR7-/- n=15).  
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Figure 5.3. IFN-γ or TNFα production by IAV-specific CD4+ T-cells in the 
lung. Lungs from mice infected with PR/8 and HK/X31 IAVs, were homogenized 
and cell suspensions were stimulated for 6 hrs with nucleoprotein (NP)311-325 
peptide. The frequency of NP311-325-specific IFN-γ+ (A) or TNFα+ (B) producing 
CD4+ T-cells and the frequencies of CD3+CD4+ T-cells in the lung (C) were 
determined in B6, MyD88-/- and TLR7-/- mice. Values shown (A & B) are the 
frequency of IFN-γ+ or TNFα+ NP311-325-specific CD4+ T-cells minus the 
frequency of cells obtained when stimulated with media. Bars are median 
values. *p<0.05 compared to NP311-325-specific B6 lung CD4+ T-cells. (B6 n=31; 
MyD88-/- n=12; TLR7-/- n=15)  
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Figure 5. 4. IAV-specific CD4+ & CD8+ T-cells in the spleen and lungs produce 
both IFN-γ and TNFα. Mice were infected with 10 PFU PR8 followed by infection, 21 
days later, with 10,000 PFU HK/X31. Seven days after the second infection, lung and 
spleen cells were stimulated for 5 to 6 hrs with  NP311-325 or NP366-374 and PA224-233 
peptide mix. The frequency of IAV-specific  IFN-γ and TNFα producing CD4+ and CD8+ 
T-cells in spleen (A)  and in the lungs (B) were determined.  Representative plots are 
shown above. 
91
signaling, but anti-IAV NP311-325 CD4+ Th1 cytokine production in the spleen was 
TLR7 independent (Figures 5.2 & 5.3).  The MyD88 dependent IL-1α/β signaling 
has been reported to influence antibody responses and CD4+ T-cells (142). To 
further investigate the MyD88 dependence on CD4+ T-cells, we infected IL-1-
deficient mice with IAV. Anti-IAV NP311-325 CD4+ Th1 cytokine production in the 
lung and spleen was also unchanged in IL-1α-/-, IL-1β-/-, IL-1αβ-/-, or IL-1R-/- mice 
compared to production by CD4+ T-cells in wild type mice (Figure 5.5). 
    
D.  Anti-IAV NP Th1 antibody responses are partially dependent on TLR7 
and MyD88 signaling in a heterosubtypic infection model.   
In C57BL/6 mice, CD4+ Th1 cells play a role in antibody isotype switching 
to IgG2c (47).  In a murine homologous IAV challenge model, anti-IAV HA 
IgG2a/c levels were reported to be TLR7 and MyD88 dependent (90).  In our 
murine heterosubtypic IAV challenge model, we also found that IgG2c directed 
against the IAV NP protein was MyD88 dependent. We observed a decrease (but 
not statistically significant) in TLR7-/- mice antibody responses.  The partial TLR7 
and MyD88 dependence for anti-NP IgG2c Ab was seen only after the secondary 
heterosubtypic IAV infection (Figure 5.6).  Th2 dependent IgG1 levels directed 
against IAV NP protein were also dependent on MyD88 signaling after the 
secondary heterosubtypic IAV infection (Figure 5.6). 
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Figure 5.5. IFN-γ or TNFα production by IAV-specific CD4+ T-cells in IL-1-
deficient mice. Frequencies of IFN-γ or TNFα-secreting nucleoprotein (NP)311-325-
specific CD4+ T-cells were assessed in IAV infected B6 and IL-1-deficient mice (IL-
1α-/-, IL-1β-/-, IL-1αβ-/-, or IL-1R-/-) in the spleen (A&B) and lungs (C&D). Mice were 
infected with PR/8 and HK/X31 IAVs, as described in Figure  5.1. Values shown  are 
the frequency of IFN-γ+ or TNFα+ NP311-325-specific CD4+ T-cells minus the 
frequency of cells obtained when stimulated with media. Bars are median values. (B6 
n=31, IL-1α-/- n=3, IL-1β-/- n=3, IL-1αβ-/- n=6, or IL-1R-/- n=6) 
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Figure 5.6. Antibody titers of nucleoprotein (NP)-specific IgG2c, IgG1 and 
total IgG in the sera of immunized mice. B6, MyD88-/- and TLR7-/- mice were 
infected with PR/8 and HK/X31 IAVs, as described in Figure 5.1. Mouse sera were 
collected 20 days after primary PR/8 IAV infection (A) and 7 days after secondary 
heterosubtypic HK/X31 IAV infection (B). *p<0.05 compared to B6 sera. (in A: B6 
n=5; MyD88-/- n=3; TLR7-/- n=3; in B: B6 n=4; MyD88-/- n=4; TLR7-/- n=4 )  
IgG2c
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
/TLR7
/MyD88
B6
not infected
IgG1
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
/TLR7
/MyD88
B6
not infected
total  IgG
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
/TLR7
/MyD88
B6
not infected
*
IgG2c
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
2.5
×1
0
4
3.0
×1
0
4
/TLR7
/MyD88
B6
not infected
*
IgG1
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
2.5
×1
0
4
3.0
×1
0
4
/TLR7
/MyD88
B6
not infected
*
total  IgG
0
5.0
×1
0
3
1.0
×1
0
4
1.5
×1
0
4
2.0
×1
0
4
2.5
×1
0
4
3.0
×1
0
4
/TLR7
/MyD88
B6
not infected
*
94
E.  A MyD88-mediated signaling pathway is required for the induction of 
some heterosubtypic CD8+ T-cell immune responses to IAV.   
We examined CD8+ T-cell immune responses to peptides NP366-374 or 
PA224-233, two MHC Class I-restricted immunodominant epitopes in C57BL/6 mice 
(10, 21).  Anti-NP or PA CD8+ T-cell type 1 cytokine production in the spleen was 
dependent on MyD88 signaling, but largely independent of TLR7 signaling 
(Figures 5.7a&b).  There were no differences in anti-NP or PA lung CD8+ T-cell 
cytokine production (IFN-γ or TNFα) and cell frequencies between wild type, 
MyD88-/-, or TLR7-/- mice (Figures 5.8a-c). There was also no difference in anti-
NP or PA spleen CD8+ T-cell type 1 cytokine production between wild type and 
IL-1α-/-, IL-1β-/-, IL-1αβ-/-, or IL-1R-/- mice (Figure 5.9).  We found that the 
frequency of CD3+CD8+ T-cells in the spleen was MyD88 dependent unlike the 
frequencies of CD3+CD4+ T-cells in the spleen which were MyD88 independent 
(Figures 5.2c & 5.7c).  This finding was confirmed by MHC Class I tetramer 
staining of NP366-374 CD8+ T-cells in the spleen (Figure 5.10).  
 
F.  Similarities and diferences between homotypic (1o PR/8 and 2o PR/8) 
and heterosubtypic (1o PR/8 and 2o HK/X31) IAV infection  
 Similar to a previous study (90), we also performed homotypic IAV 
rechallenge experiments and compared their results with our heterosubtypic IAV 
challenge model. We observed that production of IFN-γ and TNFα by CD4+ 
(Figure 5.11) and CD8+ (Figure 5.12) T-cells was dependent on MyD88 signaling 
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Figure 5.7. IFN-γ or TNFα production by IAV-specific CD8+ T-cells in the spleen. 
Splenocytes from mice infected with PR/8 and HK/X31 IAVs, were stimulated for 6 hrs 
with a mixture of nucleoprotein (NP)366-374 and polymerase (PA)224-233 peptides. NP366-374 
or PA224-233-specific cytokine-producing CD8+ T-cells were identified as CD3+CD8+CD4-
IFN-γ+ (A) or TNFα+ (B). NP366-374 or PA224-233-specific cytokine-producing CD8+ T-cells 
were analyzed in B6, MyD88-/- and TLR7-/- mice. The frequencies of spleen CD3+CD8+ 
T-cells in these mouse strains were also determined (C). Values shown (A & B) are the 
frequencies of IFN-γ+ or TNFα+ NP366-374 or PA224-233-specific splenic CD8+ T-cells 
minus frequencies of cells obtained with media stimulation. Bars are median values. 
*p<0.05 compared to NP366-374 or PA224-233-specific B6 splenic CD8+ T-cells.  (B6 n=31; 
MyD88-/- n=12; TLR7-/- n=15)  
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Figure 5.8. IFN-γ or TNFα production by IAV-specific CD8+ T-cells in the lung. 
Lungs from mice infected with PR/8 and HK/X31 IAVs,  were homogenized and 
stimulated for 6 hrs with a mixture of nucleoprotein (NP)366-374 and polymerase (PA)224-
233 peptides. MHC Class I restricted PR/8 IAV epitopes. NP366-374 or PA224-233-specific 
cytokine-producing CD8+ T-cells were identified as CD3+CD8+CD4-IFN-γ+ (A) or 
TNFα+ (B). The frequencies of lung CD3+CD8+ T-cells (C) were also determined in 
B6, MyD88-/- and TLR7-/- mice. Values shown (A & B) are the frequencies of IFN-γ+ or 
TNFα+ NP366-374 or PA224-233-specific CD8+ T-cells minus frequencies of cells obtained 
with media stimulation. Bars are median values. *p<0.05 compared to NP366-374 or 
PA224-233-specific B6 lung CD8+ T-cells. (B6 n=22; MyD88 n=12; TLR7 n=15)        
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Figure 5.9. IFN-γ or TNFα production by IAV-specific CD8+ T-cells in IL-1-deficient 
mice. IFN-γ or TNFα-secreting nucleoprotein (NP)366-374 or polymerase (PA)224-233 -
specific CD8+ T-cells in heterosubtypic IAV infected IL-1-deficient mice (IL-1α-/-, IL-1β-/-, 
IL-1αβ-/-, or IL-1R-/-) in the spleen (A&B). Mice were infected with PR/8 and HK/X31 IAVs, 
as described in Figure  5.1. Values shown are the frequencies of IFN-γ+ or TNFα+ NP366-
374 or PA224-233-specific CD8+ T-cells minus frequencies of cells obtained with media 
stimulation. Bars are median values.(B6 n=31, IL-1α-/- n=3, IL-1β-/- n=3, IL-1αβ-/- n=6, or IL-1R-/- 
n=6) 
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Figure 5.10. MHC class I influenza A virus (IAV)-specific CD8+ T-cell tetramer 
staining. MHC Class I peptide tetramers (PR/8 IAV nucleoprotein (NP)366-374/Db) were 
generated by the NIH Tetramer Facility (Atlanta, GA). Tetramer staining was 
performed for 30 min, on ice, followed by staining for CD8+ T-cells. Live/Dead Aqua 
(LDA) was used to exclude nonviable cells from analysis. At least 200,000 events were 
collected for analysis. Data was analyzed using FlowJo software (Treestar, Ashland, 
OR). The % of MHC class I NP366/Db CD8+ T-cells in two experiments were shown 
(A). For statistical analysis, the relative frequencies of MHC class I tetramer positive 
CD8+ T-cells in the spleen normalized to B6 mice (using one B6 IAV-infected mice as 
basis per experiment) following heterosubtypic IAV infection were determined (B). (B6 
n=7; MyD88 n=9; TLR7 n=7)  
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Figure 5.11. IFN-γ and TNFα production by CD4+ T-cells in the spleen and lung in 
mice infected sequentially with PR8 IAV (PR8+PR8). Splenic and lung CD4+ T-cells 
from mice infected primarily with 10 PFU PR8 followed by infection, 21 days later, with 2 
x 105 PFU PR8. Seven days after second PR8 infection, lung and spleen cells were 
stimulated for 5 to 6 hrs with NP311-325 peptide . The frequencies of IAV-specific  IFN-γ 
and TNFα producing CD4+ T-cells in spleen (A&B) and in the lungs (C&D) in B6, 
MyD88-/- and TLR7-/- infected mice were determined. Values shown are the frequencies 
of IFN-γ+ or TNFα+ CD4+ T-cells when stimulated with NP311-325 minus frequencies 
obtained when CD4+ T-cells were stimulated with media. Bars represent median values. 
*p<0.05 compared to NP311-325 stimulated B6 spleen or lung CD4+ T-cells. (B6 n=9; 
MyD88-/- n= 7; TLR7-/- n=9). 
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Figure 5.12. IFN-γ and TNFα production by spleen and lung CD8+ T-cells infected 
sequentially with PR8 IAV (PR8+PR8). Splenic and lung CD8+ T-cells from mice 
infected primarily with 10 PFU PR8 followed by infection, 21 days later, with 2 x 105 PFU 
PR8. Seven days after the second PR8 infection, lung and spleen cells were stimulated 
for 5 to 6 hrs with a NP366-374 and PA224-233 peptide mixture. The frequencies of IAV-
specific  IFN-γ and TNFα producing CD8+ T-cells in spleen (A&B) and in the lungs 
(C&D) in B6, MyD88-/- and TLR7-/- infected mice were determined. Values shown are the  
frequencies of IFN-γ+ or TNFα+ NP311-325 stimulated CD8+ T-cells minus frequencies of 
cells obtained with media stimulation. Bars represent median values. *p<0.05 compared 
to NP366-374 and PA224-233 peptide mix stimulated B6 spleen or lung CD8+ T-cells. (B6 
n=9; MyD88-/- n= 7; TLR7-/- n=9). 
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as has been previously reported (90). In contrast, frequencies of MHC class I 
IAV-specific CD8+ tetramer staining cells in homotypic IAV infection were not 
dependent on MyD88 signaling (Figure 5.10 and 5.13). 
 
G.  Chapter Discussion 
The murine model used in this study provided an experimental system for 
analyzing heterosubtypic cell-mediated immunity. We found that MyD88 
signaling, but not TLR7 signaling, was essential in heterosubtypic CD4+ and 
CD8+ T-cell responses with the exception of anti-influenza CD8+ T-cells in the 
lung where responses were MyD88 independent  
The initial induction of influenza specific immune responses is mediated 
by PRR signaling pathways.  PRR signaling pathways can be broadly 
categorized into MyD88 dependent and MyD88 independent pathways (57).  We 
examined immune responses elicited during serial sublethal heterosubtypic IAV 
infections in a murine model. This model most closely reflects serial natural IAV 
infections in humans.  Our findings point to an important role for MyD88 
dependent signaling in anti-IAV heterosubtypic memory T-cell immune 
responses.  MyD88 dependent signaling was important for Th1 cytokine 
production by anti-IAV heterosubtypic memory CD4+ T-cells while no notable 
differences in the frequencies were observed in MyD88-deficient IAV infected 
mice.  MyD88 dependent signaling was also important for NP-specific serum 
IgG2c and IgG1 antibody responses.   
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Figure 5.13. MHC class I IAV-specific CD8+ T-cell tetramer staining (homotypic, 
PR8+PR8). B6, MyD88-/- and TLR7-/- mice were infected with 10 PFU PR8 followed by 
infection, 21 days later, with  2 x 105 PFU PR8. Spleens were collected 7 days after 
homologous PR8 challenge and stained with MHC Class I peptide tetramers NP366-
374/Db. The % of MHC class I NP366/Db CD8+ T-cells in two experiments were shown 
(A). For statistical analysis, the relative frequencies of MHC class I tetramer positive 
CD8+ T-cells in the spleen normalized to B6 mice (using one B6 IAV-infected mice as 
basis per experiment) following homotypic IAV infection were determined (B). (B6 n=8; 
MyD88 n=7; TLR7 n=9)  
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 For anti-IAV heterosubtypic memory lung and spleen CD4+ T-cells, 
MyD88 signaling was not required to achieve the cell frequencies but was 
needed for Th1 cytokine production. In our murine model, there was minimal 
proliferation of anti-IAV heterosubtypic memory CD4+ T-cells by in vivo EdU 
incorporation (data not shown).  This implies that the majority of anti-IAV NP311-
325 memory lung and spleen CD4+ T-cells were recruited to the sites, likely from 
regional lymph nodes.  A similar finding has been reported for anti-IAV 
heterosubtypic memory CD8+ T-cells in a murine model (62, 89).   
MyD88 signaling is essential in the regulation of murine CD4+ T-cell 
responses in several models (31, 34, 177).  In the LCMV infection model, MyD88 
deficient mice failed to develop LCMV-specific CD4+ T-cells that can produce 
Th1 cytokines and the reconstitution of MyD88 expression in CD4+ T-cells 
rescued the LCMV-specific response (177).  In the murine model of inflammatory 
bowel disease (31), MyD88-/- CD4+ T-cells showed decreased proliferation and 
defective T-cell function both in vitro and in vivo. In an OVA-expressing 
recombinant Salmonella vaccine (63) that elicits Th1-biased cell-mediated and 
serum Ab responses in B6 mice, MyD88-/- mice exhibited greatly reduced Th1-
dependent Ab responses. The CD4+ T-cells from vaccinated MyD88 deficient 
mice also failed to produce IFN-γ (63).  
There are several ways in which MyD88 signaling could be involved in 
anti-IAV heterosubtypic memory CD4+ Th1 cytokine responses (87, 172). In 
addition to cytokine production and providing T-helper function to CD8+ T-cells, 
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IAV infection can induce cytolytic CD4+ effectors that reside in the lung (15, 16). 
Memory CD4+ T-cells can also direct enhanced protection from IAV infection 
through mobilization of immune effectors in the lung, independent of their helper 
functions (157). The MyD88-dependent IL-1 and TLR7 signaling pathways were 
reported to be important in eliciting IAV immune responses (20, 85). TLR7-
deficient mice have a Th2 bias in response to IAV and reduced levels of IAV-
specific Th1 responses (47, 90). Administration of IL-1 as mucosal adjuvant can 
confer significant protection against lethal IAV infection (85) and increased 
mortality  during IAV virus infection was observed in the absence of IL-1R1 (142). 
However, our heterosubtypic IAV data showed that dependence on TLR7 or IL-1 
signaling exclusively was minimal suggesting a much broader role of MyD88 
signaling in eliciting IAV-specific immune responses other than TLR7 and IL-1. 
Virus-induced activation of T-cells involves the dynamic interaction of 
APCs and T-cells through virus antigen presentation by APCs to T-cells, 
upregulation of co-stimulatory molecules and the production of cytokines that 
influence the activation and the generation of effector and memory-T cells. These 
crucial events and other immune cells (such as B-cells and pDCs) were 
previously reported in literature to be affected by MyD88 signaling. MyD88 
signaling is required for the DC activation/production of early inflammatory 
cytokines and the production of Th1 cytokines by T-cells against IAV infection 
(145). MyD88 signaling pathways in B-cells are essential for effective generation 
of long term humoral immunity (generation of long-lived antibody secreting 
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plasma cells) against virus infections and after influenza virus-like particle (VLP) 
vaccination (41, 76). MyD88 signaling is also critical for regulating anti-IAV B-cell 
Ab isotype switching (47). MyD88-dependent signaling is also important in 
plasmacytoid DC (pDC)-mediated protection in the lungs against IAV infection 
(74).   
MyD88 might also play an intrinsic role in Th1 cytokine production within 
CD4+ T-cells.  Such a role has been reported in a LCMV murine infection model 
in which MyD88 signaling within the CD4+ T-cells is essential for normal CD4+ T-
cell function (177). In a Toxoplasma gondii murine resistance model (95), T-cell 
expression of MyD88 is also necessary for the Th1 response and the prolonged 
resistance to Toxoplasma gondii.  
 The involvement of MyD88 (mostly via TLR7) has been examined in 
several independent IAV studies (47, 90, 100, 145) with a range of results that 
are difficult to generalize, except that all report that CD8+ T-cell responses were 
not affected by the absence of MyD88 signaling. For anti-IAV heterosubtypic 
memory CD8+ T-cells, we also observed the pulmonary Th1 cytokine response 
and cell frequency to be MyD88 independent. This finding was consistent with 
other reports that anti-IAV memory CD8+ T-cells in the lung were largely 
recruited from regional draining lymph nodes (62, 89).  
 The heterosubtypic anti-NP IgG2c antibody response was dependent on 
MyD88 signaling but not through TLR7.  This is in contrast to previously reported 
TLR7/MyD88 dependence in anti-hemagglutinin Th1 antibody responses in a 
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homologous IAV challenge model (90). In addition, we observed reduced anti-NP 
total IgG and IgG1 antibody responses. This is in contrast to previously reported 
striking Th2 bias observed in IAV-infected TLR7-/- and MyD88-/- mice (142). 
Differences in experimental conditions (such as virus strain or stock, infection 
volume, route of immunization/infection, homotypic vs heterosubtypic challenge) 
may explain these contrasting results. The MyD88-dependence observed in IAV-
specific antibody (total IgG, IgG2c and IgG1) responses suggests an important 
role not only in T-cells but other immune cells such as B-cells and pDCs (1, 41, 
47, 74, 76). The antibody response to IAV infection is largely dependent on CD4+ 
T-cell help for B cells (155). CD4+ T-cells provide cognate signals and secrete 
factors that drive B-cell activation and regulate Ab isotype switching. The MyD88-
dependence observed in heterosubtypic anti-NP antibody response may be a 
consequence of MyD88-/- CD4+ T-cell functional defect. 
Further studies that would better address the importance of the MyD88 
pathway in heterosubtypic IAV infections include adoptive transfer experiments to 
address whether MyD88 signaling is involved in the activation of APCs (Is the 
impaired CD4+ T-cell response in MyD88KO mice due to the failure of the APC 
system?) or if MyD88 is intrinsically involved in CD4+ T-cell functional maturation 
in response to heterosubtypic IAV infections. The latter could be addressed by 
the adoptive transfer of naïve MyD88-/- CD4+ T-cells into T-cell deficient mice, 
infect heterosubtypically with IAV, restimulate CD4+ T-cells with IAV-specific 
peptides and determine IFN-γ and TNFα production in response to IAV. 
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Reconstitution of MyD88 expression in MyD88-/- CD4+ T-cells by MyD88-
expressing lentivirus, as previously done in murine LCMV model (177), could 
also show the importance of intrinsic MyD88 signaling in CD4+ T-cells.  
 In IAV-specific CD8+ T-cells, we observed an interesting difference in 
MyD88 dependence between CD8+ T-cells in the spleen and in the lung. Upon 
restimulation, IFN-γ and TNFα production by MyD88-/- CD8+ T-cells in spleen 
was impaired in contrast to MyD88-/- CD8+ T-cells in the lung. This difference 
was not addressed in this study but possible explanations include (i) antigen 
persistence and the control of local T-cell memory by respiratory DCs (89) and 
the MyD88-/- effect reduction of T-cell activation in the spleen (145); (ii) MyD88-
dependent proliferation and intracellular expression of antiviral cytokines by 
CD8+T-cells may be needed in the spleen but not in the lung (due to the 
preferential localization of memory IAV T cells to the draining lymph nodes (89));  
(iii)  compromised IAV-specific CD8+ T-cell effector recall/memory as a result of 
defective CD4+ T-cell function in MyD88-/- CD4+ mice (9, 12, 47, 96); (iv) MyD88 
may be crucial for the optimal local recruitment of immune cells to the site of 
infection (46); and (v) non-MyD88 dependent signaling pathways such as 
inflammasome activation may play a role at the site of IAV infection (lung) that 
can compensate or redundant for MyD88 in inducing protective anti-IAV immunity 
(57, 58).  
In conclusion, MyD88 dependent signaling, not all of it through TLR7, 
played important roles in T-cell and antibody memory immune responses in 
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heterosubtypic IAV infections.  Homosubtypic (PR8+PR8) IAV infections further 
supported the importance of MyD88 signaling. Though not directly addressed, 
differences observed between heterosubtypic and homotypic IAV infections may 
be attributed to the protective neutralizing Abs generated during homosubtypic 
infections.  
 
H.  Chapter Summary 
We used a mouse model of heterosubtypic influenza A virus infections to 
determine the role of MyD88 signaling in CD4+ T-cell, CD8+ T-cell, and antibody 
responses. We found that MyD88 signaling played an important role in anti-IAV 
CD4+ T-cell responses in the lung and spleen and in CD8+ T-cell responses in 
the spleen following heterosubtypic and homotypic challenge with IAV. Following 
heterosubtypic IAV challenge, MyD88 dependent signaling was important for T-
helper 1 cytokine production of memory CD4+ T-cells.  TLR7 dependent 
signaling played a role only in anti-IAV heterosubtypic memory lung CD4+ Th1 
responses. Our results have important implications for the generation of effective 
universal influenza vaccines. 
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CHAPTER VI: 
FINAL SUMMARY AND IMPLICATIONS 
 
The immune response to viral infections is determined by a complex 
interplay of interactions between the pathogen and the host. Viruses not only 
need the host for replication, but the virus itself is assembled using the 
machinery of the host cell and the virion can contain material derived from the 
host cell.  Discrimination of ‘self’ from the viral ‘non-self’ is mediated by PRRs. 
RNA replicative intermediates such as ssRNA and dsRNA generated during the 
virus life cycle are detected by RNA-sensing PRRs.   
In this thesis, we focused on delineating the effects of key RNA-sensing 
PRR pathways in the innate immune response on eliciting adaptive immune T 
cell responses. With the use of RNA-like IRMs R-848 and poly I:C, we first 
looked at direct co-stimulation by RNA PAMPs and the role of RNA-sensing 
signaling pathways in CD4+ T-cells. In preliminary experiments using MACS-
enriched (not FACS sorted) CD4+ T-cells, we observed R-848 augmentation of 
IFN-γ production by CD4+ T-cells. However, R-848 augmentation was not 
observed in FACS-sorted CD4+ T-cells. This suggested production of cytokines 
by non-CD4+ T-cells in response to R-848. The use of CD4+ T-cells of high 
purity (>99.5% purity) eliminated the potential of bystander cells (e.g. NKT cells 
and γδ T-cells) to secrete cytokiness. Using FACS-sorted CD4+ T-cells from 
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specific knockout mice, we explored the RNA-sensing PRR signaling involved or 
activated by RNA-like IRMs in CD4+ T-cells. 
We found that different RNA-like IRMs can directly co-stimulate CD4+ T-
cells . The RNA-like IRM poly I:C augmented CD4+ T-cell responses better than 
R-848. The differences that we observed between R-848 and poly I:C are 
indicative of the complex interactions between the numerous PRR signaling 
pathways activated during infection by a RNA virus. The generation of virus-
specific immune responses involves the interplay of several PRRs and the 
delineation of all of these signaling events is yet to be achieved.  
On the other hand, we observed the robust proliferation and production of 
effector cytokines by CD4+ T-cells in response to poly I:C. In addition to direct 
TLR3 and RLR signaling in CD4+ T-cells, T-cells express NLRP3 and thereby 
may be activated by poly I:C (92). We have also shown that direct co-stimulation 
of CD4+ T cells by poly I:C involves the activation of PKR signaling. Though 
more definite experiments such as the use of PKR-deficient mice could further 
address this, it is suggested from the anti-CD3 stimulation experiments with 
TLR3-/-, TRIF-/-, IPS-1-/-, MDA-5-/-, NLRP3-/-, ASC-/-, TRIF-/-/MDA-5-/- and even 
MyD88-/- CD4+ T-cells that PKR or other signaling pathways were activated and 
involved in the poly I:C direct co-stimulation of CD4+ T-cells. 
We also noted a difference in the ability of R848 to induce cytokine 
production between human and mouse CD4+ T cells. Human CD4+ T-cells were 
easily stimulated to secrete IFN-γ with R-848 while there was minimal secretion 
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of IFN-γ by mouse CD4+ T cells. We explored the possibility that TLR8 signaling 
in human CD4+ T-cells may account for these differences since TLR8 signaling 
in the mouse requires poly(dT) signaling to function (37). Addition of poly(dT) to 
R-848 slightly increased IFN-γ production by mouse CD4+ T-cells. Anti-CD3 
stimulation of human CD4+ T-cells with the CL075 (TLR8/7 IRM previously 
shown to stimulate human PBMCs) resulted in the slight augmentation of IFN-γ 
production. Further definitive experiments should be performed to address TLR8 
direct co-stimulation in mouse and human CD4+ T-cells. 
We focused mainly on RNA-sensing PRR pathways on CD4+ T-cells since 
CD4+ T-cells play a pivotal role in virus clearance, primarily through the 
augmentation of the B cell and CD8+ T-cell responses (28). We next explored 
RNA-sensing PRR activation in either CD4+ T-cell or in cDCs in isolated 
cDC/CD4+ T-cell interactions (MLRs). In contrast to anti-CD3 stimulation 
experiments, we observed augmentation of Th1 cytokine production in MHC 
congenic MLRs by R-848 > poly I:C. This difference between R-848-mediated 
CD4+ Th1 responses between CD4+ T-cells alone and isolated cDC/CD4+ T-
cells interactions suggests a pivotal role for APCs in triggering cytokine 
responses in CD4+ T-cells.   
RNA-like IRMs and RNA-sensing PRRs induce Type I IFN production and 
signaling in cDCs (98, 130). With the use of IFNAR-/- cDC in MHC congenic 
MLRs, we observed abrogated CD4+ Th1 responses in both R-848 and poly I:C 
stimulated MLRs. However, we observed much lower IFN-β mRNA expression in 
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R-848 stimulated cDCs than poly I:C stimulated cDCs. This suggested type I IFN 
to be essential but not sufficient for the optimal stimulation of CD4+ Th1 
responses by RNA-like IRMs. 
R-848-mediated TLR7/MyD88 signaling has been reported to have direct 
effects on cDC and CD4+ T-cells(17, 71, 134). Using MyD88-/- and TLR7-/- mice 
to look into R-848 signaling in either cDC or CD4+ T-cells in isolated cDC/CD4+ 
interactions, we have shown that TLR7/MyD88 signaling in cDCs and TLR7-
independent but MyD88-mediated signaling in CD4+ T-cells are essential for 
R-848 induced CD4+ Th1 responses. 
The MyD88-dependence observed in both cDC and CD4+ T-cells led us to 
explore the role of IL-1R/MyD88 signaling in R-848 stimulation of CD4+ Th1 
responses. The observed partial abrogation in R-848 MHC MLRs in the absence 
of IL-1R signaling in either cDC or CD4+ T-cells led us to discover the role of 
early and rapid IL-1α and IL-1β production in RNA-like IRM driven CD4+ Th1 
responses. Taken together, the data indicated that combined actions of type I 
IFN and the early IL-1α and IL-1β production and signaling are essential for the 
robust RNA-like IRM stimulation of CD4+ Th1 responses. The essential roles of 
these cytokines were evident in the experiments involving addition and inhibition 
of IL-1 and type I IFN. 
To explore the contributions of RNA-sensing PRRs in the modulation of 
immune responses in vivo, we utilized a murine model of heterosubtypic IAV 
infections, in which, mice were infected and challenged with sublethal doses of 
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IAV PR/8 and HK/X31, respectively.  In a mouse homosubtypic IAV challenge 
model, splenic CD4+ T-cell immune responses have been previously reported to 
be dependent on TLR7/MyD88 signaling (90). In our model, we found that 
MyD88 signaling played an important role in anti-IAV heterosubtypic recall lung 
and spleen CD4+ T-cell and spleen CD4+ T-cell immune responses. However, 
these MyD88-dependent immune responses were not solely dependent on TLR7 
signaling.  TLR7 signaling played a role only in anti-IAV heterosubtypic lung 
CD4+ T-cell responses.  For anti-IAV heterosubtypic memory lung CD8+ T-cells, 
the Th1 cytokine response was MyD88-independent. 
 Our results showing differential responses in CD4+ T-cells and CD8+ T-
cells in the spleen and lung, indicate the complexities of innate recognition and 
PRR signaling. In this thesis, we did not address the roles for RLR signaling and 
NLRP3 inflammasome activation during heterosubtypic IAV infection in vivo. 
Several studies have reported that IAV is recognized by RLRs but the delineation 
of the RNA-sensing pathways and their cooperative interactions with other 
signaling pathways remains incomplete (reviewed in (141)). Several recent 
studies have established a role for the NLRP3 inflammasome during IAV 
infection but contradictory results have been obtained (reviewed in (77)). 
Elucidation and a clearer understanding of these effector pathways would be 
needed to develop improved vaccine and adjuvant strategies against seasonal 
and pandemic influenza. 
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A.  Vaccine design 
Since T-cells can mediate cross-protective (heterosubtypic) immunity 
against influenza viruses by recognition of conserved viral proteins, targeting of 
long-lived protective T-cells should be one of the goals of future vaccine 
development. Recent studies in human and mouse influenza models have 
identified CD4+ T-cells to have more prominent protective roles other than 
promoting antibody responses. In a human influenza infection model using 
volunteers seronegative to the challenge influenza virus, investigators found pre-
existing influenza-specific CD4+ T-cells, rather than CD8+ T-cells to correlate 
with disease protection (172). Their results suggested that CD4+ T-cells might 
exert direct cytotoxic activity against virus-infected cells. In mice, lethal PR/8 
infection induced a population of IFN-γ expressing cytotoxic CD4+ T-cells (16). 
These findings support the concept that perforin mediated cytotoxicity may play a 
role in protection conferred by CD4+ T-cells. In this thesis, we have shown RNA-
like IRMs to influence CD4+ Th1 responses. Although we have not studied 
whether RNA-like IRMs induced cytolytic activity in CD4+ T-cells, these 
observations strengthen the concept that CD4+ T-cells may be targeted to induce 
effective and long-lasting protection against influenza. 
With the recent progress in PRR pathways and vaccine immunology, it is 
becoming apparent that the triggering of the innate immune mechanism is the 
initial event that crucially determines the outcome of the adaptive immune 
response (23). In vaccination, vaccines are thought to contain two types of  
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immune triggers: PAMPs and damage-associated molecular patterns (DAMPs) 
(114) that can stimulate the immune system through PRR activation in APCs 
such DCs and indirectly by PRR activation in bystander cells (Figure 6.1). 
Depending on the cytokine milieu generated, CD4+ T-cells develop into various 
Th subtypes that activate cognate B-cells, induce antibody production and 
isotype switching. CD4+ T-cell help is also essential in the generation of effector 
CD8+ T-cells and long lasting memory CD8+ T-cells. In this thesis, we looked at 
an isolated cDC-CD4+ T-cell interaction that provides a snapshot on how PRRs 
can activate directly or indirectly cDCs and CD4+ T-cells (Figure 6.1). 
Another novel approach is to counteract viral subversion of innate immune 
responses by targeting an alternative PRR pathway to help elicit an adaptive 
immune response. Viruses possess different immune evasion strategies. 
Influenza NS1 is the most well-characterized of the proteins that subvert RIG-I 
mediated type I IFN responses at multiple steps and interestingly, no direct viral 
mechanism against TLR signaling has been described (6, 143). It is therefore 
possible to stimulate TLR signaling to counteract NS1 inhibition of RIG-I 
signaling. 
Currently PRRs (TLRs) are being explored as immune adjuvants 
(reviewed in (153)). In Chapter IV, we have explored the role of RNA-like IRMs 
as adjuvants. Our results provide important insights into the key signaling 
pathways responsible for RNA-like IRM CD4+ Th1 activation. TLR7 (e.g. 
imiquimod) and TLR7/8 (resiquimod) agonists were shown to contribute to the 
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Figure 6.1. Induction of adaptive immune responses to vaccines through PRR-
mediated DC activation. Vaccines may contain pathogen-associated molecular patterns 
(PAMPs) or may induce the local release of damage-associated molecular patterns 
(DAMPs). These PAMPs and DAMPs are detected directly by pattern-recognition receptors 
(PRRs) expressed by dendritic cells (DCs), leading to DC activation, maturation and 
migration to the lymph nodes. Alternatively, PRR-mediated recognition of PAMPs and 
DAMPs by bystander cells may induce the release of tissue-derived factors, such as 
cytokines, that may cooperate in the activation and orientation of the DC response. In the 
lymph nodes, the activated DCs may present antigens to T cells, provide them with co-
stimulatory signals and stimulate their differentiation by providing a favorable cytokine milieu. 
Some cytokines — such as interleukin 4 (IL 4) and type I interferons (IFNs) — may be 
provided by bystander cells. Depending on the cytokine milieu, CD4+ T cells may 
differentiate into various T helper (TH) cell subtypes that help in the activation of cognate B 
cells, antibody production and isotype switching. Depending on the balance between 
activating cytokines (and most often with the help of TH1 cell-derived IL 2), activated CD8+ T 
cells differentiate into effector and memory CD8+ T cells. In this thesis, we looked at isolated 
DC and CD4+ T-cell interactions and showed that PRRs can be activated by PAMPs in both 
DC and CD4+ T-cells. (Adapted from Desmet and Ishii, Nature Reviews Immunology July 
2012  Vol. 12 p. 479-491) 
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immunogenicity of a variety of vaccine adjuvants (107). In addition to stimulating 
T cells to proliferate and produce effector cytokines, memory T cells also respond 
to TLR-mediated activation (17). TLR7/8 stimulation promotes maturation of DCs, 
stimulates B-cells to secrete antibodies and cytokines (13) and trigger NK cells to 
produce IFN-γ (44). With a better understanding of the RNA-sensing PRR 
pathways, incorporation of RNA PAMPs or RNA-like IRMs in vaccine 
formulations as means to improve vaccine efficacy could be developed in the 
future. 
 
B.  The therapeutic applications of manipulation of PRR signaling 
pathways 
Our current understanding of the RNA-sensing PRRs pathways has led to 
numerous applications with promising potential. One therapeutic application is 
the possible use of PRRs in the management of chronic viral infections (160). In 
chronic viral hepatitis, ANA275 or isatoribine (a TLR7 agonist) has been used in 
clinical trials (54). Manipulation of the NS3/4a-inhibited dsRNA RIG-I/TRIF/IRF3 
signaling in Hepatitis C virus (HCV) infections is also in progress. The use of 
several drugs (SCH6 (Schering-Plough), BILN 2061(Boehringer-Engelheim), VX-
950 (Vertex/Mitsubishi) and SCH 503034(Schering-Plough)) that restore HCV-
inhibited cellular interferon pathways has been observed to confer antiviral 
immune response (160). 
In this thesis, we have shown RNA-like IRMs to induce Th1 responses 
and this could be useful for targeting tumors. TLR7 and TLR8 activation can 
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reverse the suppressive function of regulatory T-cells (122). When combined with 
the ability of TLR7 and TLR8 to activate DCs into producing multiple cytokines, 
this results in a strong anti-tumor response (50). New TLR7 agonists that target 
γδ T-cells are also being studied for treating carcinoma (136). The double 
stranded RNA mimic IPH-3102 is being developed for the treatment of breast 
cancer and as vaccine adjuvant (125). Hence, the activation of RNA-sensing 
PRRs is a promising approach in anti-tumor/anti-cancer strategies. 
TLR7 and TLR8 agonists have also been studied as treatment for allergies 
and asthma. Since the primary feature of an allergic response is usually a Th2 
response, this is counterbalanced by the induction of TLR7/TLR8-induced Th1 
response. This has been a focus for novel therapeutics in these disease areas 
(32, 50).   
In addition to development of PRR/TLR agonists, significant research has 
also been done on antagonists. These compounds could be used to treat sepsis, 
systemic lupus erythematosus (SLE) and rheumatoid arthritis (50). For example, 
the quinazoline derivative CDP-52364 inhibits TLR7, TLR8 and TLR9 signaling 
that also inhibits disease progression of SLE and other autoimmune diseases in 
animal models (50, 126). Delineating the critical PRR pathways and having a 
clearer understanding of the interplay of different PRR signaling pathways would 
contribute towards more effective approaches in antagonizing PRR signaling in 
certain diseases. 
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Details of PRR signaling pathways continue to be uncovered and this 
offers new opportunities in targeting innate immune signaling. The ability to 
specifically target key processes such as development of long lasting memory 
T-cells, might prevent uncontrolled infection and treatment of multiple diseases. 
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